"","STUDYID","SUBJID","USUBJID","AGE","STR01","STR01N","STR01L","STR02","STR02N","STR02L","TRT01P","TRT01PN","PARAM","PARAMCD","AVAL","CNSR","EVNTDESC","CNSDTDSC","DCTREAS"
"1","PSIVISSIG0002",1,"PSIVISSIG0002_1",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.824093086926763,0,"Death","","PROGRESSIVE DISEASE"
"2","PSIVISSIG0002",4,"PSIVISSIG0002_4",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.11156741957563,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"3","PSIVISSIG0002",5,"PSIVISSIG0002_5",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.99863107460643,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"4","PSIVISSIG0002",6,"PSIVISSIG0002_6",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.0930869267624914,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"5","PSIVISSIG0002",7,"PSIVISSIG0002_7",54,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.94113620807666,0,"PD","","PROGRESSIVE DISEASE"
"6","PSIVISSIG0002",8,"PSIVISSIG0002_8",62,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.383299110198494,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"7","PSIVISSIG0002",10,"PSIVISSIG0002_10",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.20670773442847,1,"No next-line therapy initiated","Censored at the last contact date",""
"8","PSIVISSIG0002",15,"PSIVISSIG0002_15",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.98973305954825,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"9","PSIVISSIG0002",19,"PSIVISSIG0002_19",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.35455167693361,0,"Death","","PROGRESSIVE DISEASE"
"10","PSIVISSIG0002",21,"PSIVISSIG0002_21",50,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.84531143052704,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"11","PSIVISSIG0002",22,"PSIVISSIG0002_22",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.50855578370979,0,"PD","","PROGRESSIVE DISEASE"
"12","PSIVISSIG0002",25,"PSIVISSIG0002_25",81,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.646132785763176,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"13","PSIVISSIG0002",26,"PSIVISSIG0002_26",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.993839835728953,0,"PD","","PROGRESSIVE DISEASE"
"14","PSIVISSIG0002",27,"PSIVISSIG0002_27",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.517453798767967,0,"Death","","PROGRESSIVE DISEASE"
"15","PSIVISSIG0002",31,"PSIVISSIG0002_31",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.80971937029432,0,"PD","","PROGRESSIVE DISEASE"
"16","PSIVISSIG0002",32,"PSIVISSIG0002_32",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.79603011635866,0,"PD","","PROGRESSIVE DISEASE"
"17","PSIVISSIG0002",33,"PSIVISSIG0002_33",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.314852840520192,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"18","PSIVISSIG0002",34,"PSIVISSIG0002_34",45,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.659822039698836,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"19","PSIVISSIG0002",35,"PSIVISSIG0002_35",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.48323066392882,0,"PD","","PROGRESSIVE DISEASE"
"20","PSIVISSIG0002",36,"PSIVISSIG0002_36",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.59479808350445,0,"Death","","PROGRESSIVE DISEASE"
"21","PSIVISSIG0002",38,"PSIVISSIG0002_38",48,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.0930869267624914,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"22","PSIVISSIG0002",40,"PSIVISSIG0002_40",38,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.616016427104723,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"23","PSIVISSIG0002",43,"PSIVISSIG0002_43",89,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.46201232032854,0,"Death","","PROGRESSIVE DISEASE"
"24","PSIVISSIG0002",45,"PSIVISSIG0002_45",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.18001368925394,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"25","PSIVISSIG0002",46,"PSIVISSIG0002_46",71,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.421629021218344,0,"Death","","PHYSICIAN DECISION"
"26","PSIVISSIG0002",47,"PSIVISSIG0002_47",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.72484599589322,0,"Death","","PROGRESSIVE DISEASE"
"27","PSIVISSIG0002",49,"PSIVISSIG0002_49",46,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.93429158110883,0,"PD","","PROGRESSIVE DISEASE"
"28","PSIVISSIG0002",51,"PSIVISSIG0002_51",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.19849418206708,0,"Death","","PROGRESSIVE DISEASE"
"29","PSIVISSIG0002",54,"PSIVISSIG0002_54",52,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.199863107460643,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"30","PSIVISSIG0002",57,"PSIVISSIG0002_57",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.687200547570157,0,"Death","","PHYSICIAN DECISION"
"31","PSIVISSIG0002",58,"PSIVISSIG0002_58",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.69062286105407,1,"No next-line therapy initiated","Censored at the last contact date",""
"32","PSIVISSIG0002",59,"PSIVISSIG0002_59",65,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.355920602327173,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"33","PSIVISSIG0002",62,"PSIVISSIG0002_62",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.49965776865161,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"34","PSIVISSIG0002",66,"PSIVISSIG0002_66",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.637234770705,0,"PD","","PROGRESSIVE DISEASE"
"35","PSIVISSIG0002",67,"PSIVISSIG0002_67",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.673511293634497,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"36","PSIVISSIG0002",68,"PSIVISSIG0002_68",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.67556468172485,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"37","PSIVISSIG0002",73,"PSIVISSIG0002_73",45,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.654346338124572,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"38","PSIVISSIG0002",74,"PSIVISSIG0002_74",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.676249144421629,0,"Death","","PROGRESSIVE DISEASE"
"39","PSIVISSIG0002",76,"PSIVISSIG0002_76",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.87268993839836,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"40","PSIVISSIG0002",78,"PSIVISSIG0002_78",66,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.63791923340178,1,"No next-line therapy initiated","Censored at the last contact date",""
"41","PSIVISSIG0002",82,"PSIVISSIG0002_82",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.06707734428474,1,"No next-line therapy initiated","Censored at the last contact date",""
"42","PSIVISSIG0002",83,"PSIVISSIG0002_83",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.08350444900753,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"43","PSIVISSIG0002",86,"PSIVISSIG0002_86",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.03969883641342,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"44","PSIVISSIG0002",88,"PSIVISSIG0002_88",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.56605065023956,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"45","PSIVISSIG0002",90,"PSIVISSIG0002_90",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.60643394934976,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"46","PSIVISSIG0002",91,"PSIVISSIG0002_91",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.19301848049281,1,"No next-line therapy initiated","Censored at the last contact date",""
"47","PSIVISSIG0002",96,"PSIVISSIG0002_96",56,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.12251882272416,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"48","PSIVISSIG0002",97,"PSIVISSIG0002_97",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.506502395619439,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"49","PSIVISSIG0002",98,"PSIVISSIG0002_98",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.29979466119096,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"50","PSIVISSIG0002",103,"PSIVISSIG0002_103",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.91170431211499,0,"PD","","DEATH"
"51","PSIVISSIG0002",106,"PSIVISSIG0002_106",76,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.72758384668036,1,"No next-line therapy initiated","Censored at the last contact date",""
"52","PSIVISSIG0002",108,"PSIVISSIG0002_108",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.342231348391513,1,"No next-line therapy initiated","Censored at the last contact date",""
"53","PSIVISSIG0002",110,"PSIVISSIG0002_110",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.07049965776865,0,"PD","","PHYSICIAN DECISION"
"54","PSIVISSIG0002",111,"PSIVISSIG0002_111",56,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.09787816563997,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"55","PSIVISSIG0002",114,"PSIVISSIG0002_114",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.75359342915811,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"56","PSIVISSIG0002",117,"PSIVISSIG0002_117",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.362765229295,1,"No next-line therapy initiated","Censored at the last contact date",""
"57","PSIVISSIG0002",118,"PSIVISSIG0002_118",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.1047227926078,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"58","PSIVISSIG0002",121,"PSIVISSIG0002_121",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.1088295687885,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"59","PSIVISSIG0002",123,"PSIVISSIG0002_123",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.9637234770705,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"60","PSIVISSIG0002",127,"PSIVISSIG0002_127",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.71115674195756,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"61","PSIVISSIG0002",128,"PSIVISSIG0002_128",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.383299110198494,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"62","PSIVISSIG0002",130,"PSIVISSIG0002_130",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.86858316221766,1,"No next-line therapy initiated","Censored at the last contact date",""
"63","PSIVISSIG0002",133,"PSIVISSIG0002_133",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.28405201916496,0,"Death","","PROGRESSIVE DISEASE"
"64","PSIVISSIG0002",134,"PSIVISSIG0002_134",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.19028062970568,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"65","PSIVISSIG0002",137,"PSIVISSIG0002_137",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.698151950718686,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"66","PSIVISSIG0002",142,"PSIVISSIG0002_142",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.78713210130048,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"67","PSIVISSIG0002",143,"PSIVISSIG0002_143",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.04243668720055,0,"Death","","PROGRESSIVE DISEASE"
"68","PSIVISSIG0002",146,"PSIVISSIG0002_146",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.09171800136893,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"69","PSIVISSIG0002",148,"PSIVISSIG0002_148",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.82067077344285,0,"PD","","PROGRESSIVE DISEASE"
"70","PSIVISSIG0002",153,"PSIVISSIG0002_153",92,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.94866529774127,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"71","PSIVISSIG0002",157,"PSIVISSIG0002_157",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.383299110198494,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"72","PSIVISSIG0002",159,"PSIVISSIG0002_159",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.09377138945927,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"73","PSIVISSIG0002",163,"PSIVISSIG0002_163",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.87268993839836,0,"PD","","PHYSICIAN DECISION"
"74","PSIVISSIG0002",165,"PSIVISSIG0002_165",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.55989048596851,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"75","PSIVISSIG0002",166,"PSIVISSIG0002_166",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.347707049965777,0,"Death","","PROGRESSIVE DISEASE"
"76","PSIVISSIG0002",169,"PSIVISSIG0002_169",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.23613963039014,1,"No next-line therapy initiated","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"77","PSIVISSIG0002",170,"PSIVISSIG0002_170",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.74401095140315,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"78","PSIVISSIG0002",174,"PSIVISSIG0002_174",75,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.19575633127995,0,"PD","","PROGRESSIVE DISEASE"
"79","PSIVISSIG0002",175,"PSIVISSIG0002_175",66,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.835044490075291,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"80","PSIVISSIG0002",179,"PSIVISSIG0002_179",54,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.898015058179329,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"81","PSIVISSIG0002",180,"PSIVISSIG0002_180",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.665297741273101,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"82","PSIVISSIG0002",181,"PSIVISSIG0002_181",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.20054757015743,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"83","PSIVISSIG0002",182,"PSIVISSIG0002_182",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.56331279945243,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"84","PSIVISSIG0002",185,"PSIVISSIG0002_185",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.57837097878166,1,"No next-line therapy initiated","Censored at the last contact date",""
"85","PSIVISSIG0002",186,"PSIVISSIG0002_186",75,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.88090349075975,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"86","PSIVISSIG0002",191,"PSIVISSIG0002_191",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.12936344969199,1,"No next-line therapy initiated","Censored at the last contact date",""
"87","PSIVISSIG0002",192,"PSIVISSIG0002_192",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.64271047227926,0,"Death","","PROGRESSIVE DISEASE"
"88","PSIVISSIG0002",195,"PSIVISSIG0002_195",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.407939767282683,1,"No next-line therapy initiated","Censored at the last contact date",""
"89","PSIVISSIG0002",196,"PSIVISSIG0002_196",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.782340862423,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"90","PSIVISSIG0002",203,"PSIVISSIG0002_203",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.892539356605065,0,"PD","","PROGRESSIVE DISEASE"
"91","PSIVISSIG0002",208,"PSIVISSIG0002_208",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.27857631759069,0,"PD","","PROGRESSIVE DISEASE"
"92","PSIVISSIG0002",211,"PSIVISSIG0002_211",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.18480492813142,1,"No next-line therapy initiated","Censored at the last contact date",""
"93","PSIVISSIG0002",212,"PSIVISSIG0002_212",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.04312114989733,0,"PD","","PHYSICIAN DECISION"
"94","PSIVISSIG0002",213,"PSIVISSIG0002_213",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.05475701574264,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"95","PSIVISSIG0002",214,"PSIVISSIG0002_214",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.59069130732375,1,"No next-line therapy initiated","Censored at the last contact date",""
"96","PSIVISSIG0002",215,"PSIVISSIG0002_215",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.81793292265572,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"97","PSIVISSIG0002",216,"PSIVISSIG0002_216",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.72689938398357,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"98","PSIVISSIG0002",220,"PSIVISSIG0002_220",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.20123203285421,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"99","PSIVISSIG0002",222,"PSIVISSIG0002_222",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.83709787816564,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"100","PSIVISSIG0002",223,"PSIVISSIG0002_223",41,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.202600958247775,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"101","PSIVISSIG0002",224,"PSIVISSIG0002_224",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.97878165639973,1,"No next-line therapy initiated","Censored at the last contact date",""
"102","PSIVISSIG0002",226,"PSIVISSIG0002_226",72,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.98767967145791,0,"PD","","PROGRESSIVE DISEASE"
"103","PSIVISSIG0002",229,"PSIVISSIG0002_229",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.77138945927447,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"104","PSIVISSIG0002",230,"PSIVISSIG0002_230",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.00958247775496,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"105","PSIVISSIG0002",231,"PSIVISSIG0002_231",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.81382614647502,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"106","PSIVISSIG0002",233,"PSIVISSIG0002_233",42,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.698151950718686,0,"Death","","PROGRESSIVE DISEASE"
"107","PSIVISSIG0002",234,"PSIVISSIG0002_234",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.08350444900753,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"108","PSIVISSIG0002",240,"PSIVISSIG0002_240",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.35934291581109,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"109","PSIVISSIG0002",241,"PSIVISSIG0002_241",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.884325804243669,0,"PD","","PROGRESSIVE DISEASE"
"110","PSIVISSIG0002",243,"PSIVISSIG0002_243",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.681724845995893,0,"Death","","PROGRESSIVE DISEASE"
"111","PSIVISSIG0002",244,"PSIVISSIG0002_244",42,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.684462696783025,0,"Death","","PROGRESSIVE DISEASE"
"112","PSIVISSIG0002",247,"PSIVISSIG0002_247",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.23956194387406,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"113","PSIVISSIG0002",248,"PSIVISSIG0002_248",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.457221081451061,1,"No next-line therapy initiated","Censored at the last contact date",""
"114","PSIVISSIG0002",249,"PSIVISSIG0002_249",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.501026694045175,1,"No next-line therapy initiated","Censored at the last contact date",""
"115","PSIVISSIG0002",257,"PSIVISSIG0002_257",56,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.84804928131417,0,"PD","","PROGRESSIVE DISEASE"
"116","PSIVISSIG0002",258,"PSIVISSIG0002_258",60,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.824093086926763,0,"PD","","PROGRESSIVE DISEASE"
"117","PSIVISSIG0002",259,"PSIVISSIG0002_259",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.57289527720739,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"118","PSIVISSIG0002",260,"PSIVISSIG0002_260",32,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.659822039698836,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"119","PSIVISSIG0002",262,"PSIVISSIG0002_262",45,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.659822039698836,0,"PD","","PROGRESSIVE DISEASE"
"120","PSIVISSIG0002",264,"PSIVISSIG0002_264",53,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.61533196440794,0,"PD","","PROGRESSIVE DISEASE"
"121","PSIVISSIG0002",266,"PSIVISSIG0002_266",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.793976728268309,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"122","PSIVISSIG0002",267,"PSIVISSIG0002_267",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.46748802190281,0,"PD","","PROGRESSIVE DISEASE"
"123","PSIVISSIG0002",275,"PSIVISSIG0002_275",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.944558521560575,1,"No next-line therapy initiated","Censored at the last contact date",""
"124","PSIVISSIG0002",276,"PSIVISSIG0002_276",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.662559890485969,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"125","PSIVISSIG0002",277,"PSIVISSIG0002_277",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.65913757700205,0,"Death","","PROGRESSIVE DISEASE"
"126","PSIVISSIG0002",278,"PSIVISSIG0002_278",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.362765229295,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"127","PSIVISSIG0002",279,"PSIVISSIG0002_279",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.884325804243669,0,"PD","","PROGRESSIVE DISEASE"
"128","PSIVISSIG0002",281,"PSIVISSIG0002_281",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.12388774811773,1,"No next-line therapy initiated","Censored at the last contact date",""
"129","PSIVISSIG0002",282,"PSIVISSIG0002_282",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.91375770020534,0,"PD","","PROGRESSIVE DISEASE"
"130","PSIVISSIG0002",284,"PSIVISSIG0002_284",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.334017796030116,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"131","PSIVISSIG0002",291,"PSIVISSIG0002_291",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.840520191649555,0,"PD","","PROGRESSIVE DISEASE"
"132","PSIVISSIG0002",293,"PSIVISSIG0002_293",56,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.20807665982204,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"133","PSIVISSIG0002",295,"PSIVISSIG0002_295",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.99794661190965,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"134","PSIVISSIG0002",296,"PSIVISSIG0002_296",46,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.98357289527721,0,"PD","","PROGRESSIVE DISEASE"
"135","PSIVISSIG0002",297,"PSIVISSIG0002_297",69,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.5605749486653,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"136","PSIVISSIG0002",298,"PSIVISSIG0002_298",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.2662559890486,1,"No next-line therapy initiated","Censored at the last contact date",""
"137","PSIVISSIG0002",301,"PSIVISSIG0002_301",43,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.197125256673511,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"138","PSIVISSIG0002",302,"PSIVISSIG0002_302",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.94729637234771,0,"Death","","PROGRESSIVE DISEASE"
"139","PSIVISSIG0002",305,"PSIVISSIG0002_305",52,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.65160848733744,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"140","PSIVISSIG0002",310,"PSIVISSIG0002_310",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.427104722792608,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"141","PSIVISSIG0002",311,"PSIVISSIG0002_311",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.974674880219028,1,"No next-line therapy initiated","Censored at the last contact date",""
"142","PSIVISSIG0002",312,"PSIVISSIG0002_312",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.06297056810404,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"143","PSIVISSIG0002",314,"PSIVISSIG0002_314",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",5.24572210814511,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"144","PSIVISSIG0002",315,"PSIVISSIG0002_315",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.8507871321013,0,"PD","","PROGRESSIVE DISEASE"
"145","PSIVISSIG0002",317,"PSIVISSIG0002_317",82,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.51950718685832,0,"PD","","ADVERSE EVENT"
"146","PSIVISSIG0002",319,"PSIVISSIG0002_319",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.40999315537303,0,"Death","","PROGRESSIVE DISEASE"
"147","PSIVISSIG0002",320,"PSIVISSIG0002_320",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.19507186858316,0,"PD","","PROGRESSIVE DISEASE"
"148","PSIVISSIG0002",321,"PSIVISSIG0002_321",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.29774127310062,0,"PD","","PROGRESSIVE DISEASE"
"149","PSIVISSIG0002",322,"PSIVISSIG0002_322",74,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.6694045174538,1,"No next-line therapy initiated","Censored at the last contact date",""
"150","PSIVISSIG0002",324,"PSIVISSIG0002_324",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.04654346338125,1,"No next-line therapy initiated","Censored at the last contact date",""
"151","PSIVISSIG0002",325,"PSIVISSIG0002_325",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.01779603011636,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"152","PSIVISSIG0002",326,"PSIVISSIG0002_326",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.83709787816564,0,"PD","","PHYSICIAN DECISION"
"153","PSIVISSIG0002",327,"PSIVISSIG0002_327",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.69130732375086,1,"No next-line therapy initiated","Censored at the last contact date",""
"154","PSIVISSIG0002",328,"PSIVISSIG0002_328",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.23477070499658,0,"Death","","PROGRESSIVE DISEASE"
"155","PSIVISSIG0002",329,"PSIVISSIG0002_329",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.7015742642026,1,"No next-line therapy initiated","Censored at the last contact date",""
"156","PSIVISSIG0002",331,"PSIVISSIG0002_331",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.02053388090349,0,"PD","","PROGRESSIVE DISEASE"
"157","PSIVISSIG0002",334,"PSIVISSIG0002_334",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.82067077344285,1,"Ongoing on first next-line therapy","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"158","PSIVISSIG0002",335,"PSIVISSIG0002_335",73,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.47843942505133,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"159","PSIVISSIG0002",336,"PSIVISSIG0002_336",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.65092402464066,0,"Death","","PROGRESSIVE DISEASE"
"160","PSIVISSIG0002",339,"PSIVISSIG0002_339",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.10540725530459,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"161","PSIVISSIG0002",340,"PSIVISSIG0002_340",52,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.95687885010267,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"162","PSIVISSIG0002",343,"PSIVISSIG0002_343",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.818617385352498,0,"PD","","PROGRESSIVE DISEASE"
"163","PSIVISSIG0002",344,"PSIVISSIG0002_344",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.336755646817248,1,"No next-line therapy initiated","Censored at the last contact date",""
"164","PSIVISSIG0002",345,"PSIVISSIG0002_345",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.761122518822724,0,"PD","","PROGRESSIVE DISEASE"
"165","PSIVISSIG0002",347,"PSIVISSIG0002_347",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.78986995208761,1,"No next-line therapy initiated","Censored at the last contact date",""
"166","PSIVISSIG0002",351,"PSIVISSIG0002_351",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.303901437371663,0,"Death","","DEATH"
"167","PSIVISSIG0002",355,"PSIVISSIG0002_355",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.58110882956879,1,"No next-line therapy initiated","Censored at the last contact date",""
"168","PSIVISSIG0002",357,"PSIVISSIG0002_357",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.91375770020534,0,"PD","","PROGRESSIVE DISEASE"
"169","PSIVISSIG0002",358,"PSIVISSIG0002_358",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.49144421629021,1,"No next-line therapy initiated","Censored at the last contact date",""
"170","PSIVISSIG0002",363,"PSIVISSIG0002_363",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.35455167693361,0,"Death","","PROGRESSIVE DISEASE"
"171","PSIVISSIG0002",364,"PSIVISSIG0002_364",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.94045174537988,1,"No next-line therapy initiated","Censored at the last contact date",""
"172","PSIVISSIG0002",366,"PSIVISSIG0002_366",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.84804928131417,0,"PD","","PROGRESSIVE DISEASE"
"173","PSIVISSIG0002",367,"PSIVISSIG0002_367",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.889801505817933,0,"PD","","DEATH"
"174","PSIVISSIG0002",368,"PSIVISSIG0002_368",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.50513347022587,1,"No next-line therapy initiated","Censored at the last contact date",""
"175","PSIVISSIG0002",369,"PSIVISSIG0002_369",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.969199178644764,0,"PD","","PROGRESSIVE DISEASE"
"176","PSIVISSIG0002",370,"PSIVISSIG0002_370",75,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.19849418206708,0,"PD","","PROGRESSIVE DISEASE"
"177","PSIVISSIG0002",371,"PSIVISSIG0002_371",54,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.922655715263518,0,"Death","","DEATH"
"178","PSIVISSIG0002",372,"PSIVISSIG0002_372",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.90554414784394,1,"No next-line therapy initiated","Censored at the last contact date",""
"179","PSIVISSIG0002",373,"PSIVISSIG0002_373",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.681724845995893,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"180","PSIVISSIG0002",374,"PSIVISSIG0002_374",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.46680355920602,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"181","PSIVISSIG0002",375,"PSIVISSIG0002_375",65,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.364134154688569,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"182","PSIVISSIG0002",377,"PSIVISSIG0002_377",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.971937029431896,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"183","PSIVISSIG0002",378,"PSIVISSIG0002_378",72,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.99041752224504,0,"PD","","PROGRESSIVE DISEASE"
"184","PSIVISSIG0002",379,"PSIVISSIG0002_379",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.657084188911704,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"185","PSIVISSIG0002",380,"PSIVISSIG0002_380",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.60164271047228,1,"Second next-line therapy initiated","Censored at the end date of the next-line therapy","PROGRESSIVE DISEASE"
"186","PSIVISSIG0002",384,"PSIVISSIG0002_384",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.34360027378508,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"187","PSIVISSIG0002",385,"PSIVISSIG0002_385",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",5.28952772073922,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"188","PSIVISSIG0002",387,"PSIVISSIG0002_387",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.09650924024641,1,"No next-line therapy initiated","Censored at the last contact date",""
"189","PSIVISSIG0002",388,"PSIVISSIG0002_388",47,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.522929500342231,1,"No next-line therapy initiated","Censored at the last contact date","PROTOCOL DEVIATION"
"190","PSIVISSIG0002",390,"PSIVISSIG0002_390",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.22518822724162,1,"No next-line therapy initiated","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"191","PSIVISSIG0002",391,"PSIVISSIG0002_391",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.42094455852156,0,"Death","","PROGRESSIVE DISEASE"
"192","PSIVISSIG0002",392,"PSIVISSIG0002_392",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.490075290896646,0,"Death","","PROGRESSIVE DISEASE"
"193","PSIVISSIG0002",394,"PSIVISSIG0002_394",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.802190280629706,1,"No next-line therapy initiated","Censored at the last contact date",""
"194","PSIVISSIG0002",395,"PSIVISSIG0002_395",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.28131416837782,0,"PD","","PROGRESSIVE DISEASE"
"195","PSIVISSIG0002",396,"PSIVISSIG0002_396",52,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.65160848733744,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"196","PSIVISSIG0002",398,"PSIVISSIG0002_398",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.08350444900753,0,"PD","","PROGRESSIVE DISEASE"
"197","PSIVISSIG0002",401,"PSIVISSIG0002_401",48,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.427104722792608,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"198","PSIVISSIG0002",402,"PSIVISSIG0002_402",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.840520191649555,0,"Death","","PROGRESSIVE DISEASE"
"199","PSIVISSIG0002",406,"PSIVISSIG0002_406",65,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.539356605065024,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"200","PSIVISSIG0002",410,"PSIVISSIG0002_410",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.3223819301848,0,"Death","","PROGRESSIVE DISEASE"
"201","PSIVISSIG0002",411,"PSIVISSIG0002_411",54,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.917180013689254,0,"Death","","DEATH"
"202","PSIVISSIG0002",412,"PSIVISSIG0002_412",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.927446954141,0,"Death","","PROGRESSIVE DISEASE"
"203","PSIVISSIG0002",413,"PSIVISSIG0002_413",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.04791238877481,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"204","PSIVISSIG0002",415,"PSIVISSIG0002_415",50,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.85626283367556,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"205","PSIVISSIG0002",417,"PSIVISSIG0002_417",74,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.65023956194387,1,"No next-line therapy initiated","Censored at the last contact date",""
"206","PSIVISSIG0002",418,"PSIVISSIG0002_418",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.75359342915811,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"207","PSIVISSIG0002",419,"PSIVISSIG0002_419",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.97399041752225,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"208","PSIVISSIG0002",420,"PSIVISSIG0002_420",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.2539356605065,0,"Death","","PROGRESSIVE DISEASE"
"209","PSIVISSIG0002",421,"PSIVISSIG0002_421",75,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.89459274469541,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"210","PSIVISSIG0002",422,"PSIVISSIG0002_422",55,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.498288843258042,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"211","PSIVISSIG0002",423,"PSIVISSIG0002_423",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.97741273100616,0,"PD","","PROGRESSIVE DISEASE"
"212","PSIVISSIG0002",424,"PSIVISSIG0002_424",56,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.84531143052704,0,"PD","","PROGRESSIVE DISEASE"
"213","PSIVISSIG0002",426,"PSIVISSIG0002_426",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.51950718685832,0,"PD","","PROGRESSIVE DISEASE"
"214","PSIVISSIG0002",427,"PSIVISSIG0002_427",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.57426420260096,1,"Second next-line therapy initiated","Censored at the end date of the next-line therapy","PROGRESSIVE DISEASE"
"215","PSIVISSIG0002",428,"PSIVISSIG0002_428",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.55715263518138,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"216","PSIVISSIG0002",431,"PSIVISSIG0002_431",43,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.02874743326489,0,"PD","","PROGRESSIVE DISEASE"
"217","PSIVISSIG0002",432,"PSIVISSIG0002_432",48,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.0958247775496235,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"218","PSIVISSIG0002",437,"PSIVISSIG0002_437",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.57426420260096,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"219","PSIVISSIG0002",438,"PSIVISSIG0002_438",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.791238877481177,1,"No next-line therapy initiated","Censored at the last contact date",""
"220","PSIVISSIG0002",440,"PSIVISSIG0002_440",92,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.93497604380561,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"221","PSIVISSIG0002",441,"PSIVISSIG0002_441",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.36824093086927,0,"PD","","PROGRESSIVE DISEASE"
"222","PSIVISSIG0002",443,"PSIVISSIG0002_443",42,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.668035592060233,0,"Death","","PROGRESSIVE DISEASE"
"223","PSIVISSIG0002",444,"PSIVISSIG0002_444",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.418891170431211,0,"Death","","PROGRESSIVE DISEASE"
"224","PSIVISSIG0002",445,"PSIVISSIG0002_445",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.0903490759753593,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"225","PSIVISSIG0002",449,"PSIVISSIG0002_449",84,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.380561259411362,0,"Death","","DEATH"
"226","PSIVISSIG0002",452,"PSIVISSIG0002_452",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.61533196440794,0,"PD","","PROGRESSIVE DISEASE"
"227","PSIVISSIG0002",455,"PSIVISSIG0002_455",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.59890485968515,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"228","PSIVISSIG0002",457,"PSIVISSIG0002_457",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.927446954141,0,"PD","","PROGRESSIVE DISEASE"
"229","PSIVISSIG0002",458,"PSIVISSIG0002_458",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.30595482546201,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"230","PSIVISSIG0002",459,"PSIVISSIG0002_459",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.824093086926763,0,"PD","","PROGRESSIVE DISEASE"
"231","PSIVISSIG0002",463,"PSIVISSIG0002_463",41,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.183436002737851,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"232","PSIVISSIG0002",466,"PSIVISSIG0002_466",73,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.4839151266256,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"233","PSIVISSIG0002",467,"PSIVISSIG0002_467",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.13415468856947,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"234","PSIVISSIG0002",469,"PSIVISSIG0002_469",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.12046543463381,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"235","PSIVISSIG0002",471,"PSIVISSIG0002_471",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.34633812457221,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"236","PSIVISSIG0002",472,"PSIVISSIG0002_472",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.63791923340178,0,"Death","","DEATH"
"237","PSIVISSIG0002",473,"PSIVISSIG0002_473",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.56331279945243,0,"PD","","PROGRESSIVE DISEASE"
"238","PSIVISSIG0002",474,"PSIVISSIG0002_474",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.31690622861054,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"239","PSIVISSIG0002",477,"PSIVISSIG0002_477",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.657084188911704,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"240","PSIVISSIG0002",478,"PSIVISSIG0002_478",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.62970568104038,1,"No next-line therapy initiated","Censored at the last contact date",""
"241","PSIVISSIG0002",480,"PSIVISSIG0002_480",92,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.95414099931554,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"242","PSIVISSIG0002",481,"PSIVISSIG0002_481",88,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.955509924709103,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"243","PSIVISSIG0002",482,"PSIVISSIG0002_482",85,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.10403832991102,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"244","PSIVISSIG0002",484,"PSIVISSIG0002_484",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.213552361396304,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"245","PSIVISSIG0002",486,"PSIVISSIG0002_486",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.58316221765914,1,"No next-line therapy initiated","Censored at the last contact date",""
"246","PSIVISSIG0002",491,"PSIVISSIG0002_491",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.08966461327858,0,"PD","","PROGRESSIVE DISEASE"
"247","PSIVISSIG0002",492,"PSIVISSIG0002_492",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.20739219712526,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"248","PSIVISSIG0002",493,"PSIVISSIG0002_493",88,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.933607118412047,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"249","PSIVISSIG0002",494,"PSIVISSIG0002_494",47,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.492813141683778,1,"No next-line therapy initiated","Censored at the last contact date","PROTOCOL DEVIATION"
"250","PSIVISSIG0002",497,"PSIVISSIG0002_497",45,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.5523613963039,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"251","PSIVISSIG0002",503,"PSIVISSIG0002_503",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.45106091718001,0,"PD","","PROGRESSIVE DISEASE"
"252","PSIVISSIG0002",504,"PSIVISSIG0002_504",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.884325804243669,0,"Death","","PROGRESSIVE DISEASE"
"253","PSIVISSIG0002",505,"PSIVISSIG0002_505",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.796714579055442,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"254","PSIVISSIG0002",506,"PSIVISSIG0002_506",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.388774811772758,0,"Death","","PROGRESSIVE DISEASE"
"255","PSIVISSIG0002",507,"PSIVISSIG0002_507",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.9356605065024,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"256","PSIVISSIG0002",509,"PSIVISSIG0002_509",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.90554414784394,1,"No next-line therapy initiated","Censored at the last contact date",""
"257","PSIVISSIG0002",511,"PSIVISSIG0002_511",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.75701574264203,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"258","PSIVISSIG0002",512,"PSIVISSIG0002_512",69,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.88364134154689,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"259","PSIVISSIG0002",513,"PSIVISSIG0002_513",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.71115674195756,0,"Death","","PROGRESSIVE DISEASE"
"260","PSIVISSIG0002",515,"PSIVISSIG0002_515",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.08350444900753,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"261","PSIVISSIG0002",517,"PSIVISSIG0002_517",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.00958247775496,0,"Death","","DEATH"
"262","PSIVISSIG0002",518,"PSIVISSIG0002_518",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.13552361396304,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"263","PSIVISSIG0002",520,"PSIVISSIG0002_520",52,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.65160848733744,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"264","PSIVISSIG0002",526,"PSIVISSIG0002_526",45,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.698151950718686,0,"PD","","PROGRESSIVE DISEASE"
"265","PSIVISSIG0002",528,"PSIVISSIG0002_528",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.36824093086927,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"266","PSIVISSIG0002",531,"PSIVISSIG0002_531",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.13415468856947,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"267","PSIVISSIG0002",535,"PSIVISSIG0002_535",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.11088295687885,0,"PD","","PROGRESSIVE DISEASE"
"268","PSIVISSIG0002",538,"PSIVISSIG0002_538",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.05612594113621,0,"Death","","PROGRESSIVE DISEASE"
"269","PSIVISSIG0002",541,"PSIVISSIG0002_541",62,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.70362765229295,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"270","PSIVISSIG0002",544,"PSIVISSIG0002_544",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.93771389459274,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"271","PSIVISSIG0002",550,"PSIVISSIG0002_550",55,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.596851471594798,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"272","PSIVISSIG0002",554,"PSIVISSIG0002_554",62,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.383299110198494,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"273","PSIVISSIG0002",555,"PSIVISSIG0002_555",54,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.9192334017796,0,"PD","","PROGRESSIVE DISEASE"
"274","PSIVISSIG0002",562,"PSIVISSIG0002_562",56,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.86447638603696,0,"PD","","PROGRESSIVE DISEASE"
"275","PSIVISSIG0002",563,"PSIVISSIG0002_563",45,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.947296372347707,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"276","PSIVISSIG0002",564,"PSIVISSIG0002_564",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.941820670773443,1,"No next-line therapy initiated","Censored at the last contact date",""
"277","PSIVISSIG0002",565,"PSIVISSIG0002_565",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.70499657768652,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"278","PSIVISSIG0002",566,"PSIVISSIG0002_566",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.58521560574949,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"279","PSIVISSIG0002",567,"PSIVISSIG0002_567",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.08145106091718,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"280","PSIVISSIG0002",571,"PSIVISSIG0002_571",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.676249144421629,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"281","PSIVISSIG0002",576,"PSIVISSIG0002_576",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.59753593429158,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"282","PSIVISSIG0002",577,"PSIVISSIG0002_577",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.49965776865161,0,"PD","","PROGRESSIVE DISEASE"
"283","PSIVISSIG0002",580,"PSIVISSIG0002_580",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.856947296372348,0,"PD","","PROGRESSIVE DISEASE"
"284","PSIVISSIG0002",584,"PSIVISSIG0002_584",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.17659137577002,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"285","PSIVISSIG0002",585,"PSIVISSIG0002_585",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.936344969199179,0,"PD","","PROGRESSIVE DISEASE"
"286","PSIVISSIG0002",586,"PSIVISSIG0002_586",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.16837782340862,0,"PD","","PROGRESSIVE DISEASE"
"287","PSIVISSIG0002",587,"PSIVISSIG0002_587",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.98973305954825,0,"PD","","PROGRESSIVE DISEASE"
"288","PSIVISSIG0002",588,"PSIVISSIG0002_588",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.774811772758385,0,"PD","","PROGRESSIVE DISEASE"
"289","PSIVISSIG0002",590,"PSIVISSIG0002_590",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.47501711156742,1,"No next-line therapy initiated","Censored at the last contact date",""
"290","PSIVISSIG0002",591,"PSIVISSIG0002_591",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.24777549623546,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"291","PSIVISSIG0002",592,"PSIVISSIG0002_592",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.23887748117728,1,"No next-line therapy initiated","Censored at the last contact date",""
"292","PSIVISSIG0002",593,"PSIVISSIG0002_593",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.34907597535934,0,"PD","","PROGRESSIVE DISEASE"
"293","PSIVISSIG0002",594,"PSIVISSIG0002_594",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.829568788501027,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"294","PSIVISSIG0002",600,"PSIVISSIG0002_600",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.744695414099932,0,"PD","","PROGRESSIVE DISEASE"
"295","PSIVISSIG0002",601,"PSIVISSIG0002_601",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.04517453798768,0,"Death","","PROGRESSIVE DISEASE"
"296","PSIVISSIG0002",603,"PSIVISSIG0002_603",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.80698151950719,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"297","PSIVISSIG0002",604,"PSIVISSIG0002_604",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.81930184804928,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"298","PSIVISSIG0002",607,"PSIVISSIG0002_607",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.930869267624914,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"299","PSIVISSIG0002",611,"PSIVISSIG0002_611",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.05612594113621,0,"PD","","PROGRESSIVE DISEASE"
"300","PSIVISSIG0002",613,"PSIVISSIG0002_613",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.08145106091718,1,"Ongoing on first next-line therapy","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"301","PSIVISSIG0002",616,"PSIVISSIG0002_616",82,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.42368240930869,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"302","PSIVISSIG0002",617,"PSIVISSIG0002_617",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.62217659137577,0,"Death","","PROGRESSIVE DISEASE"
"303","PSIVISSIG0002",620,"PSIVISSIG0002_620",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.53867214236824,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"304","PSIVISSIG0002",621,"PSIVISSIG0002_621",55,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.53388090349076,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"305","PSIVISSIG0002",623,"PSIVISSIG0002_623",43,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.164271047227926,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"306","PSIVISSIG0002",625,"PSIVISSIG0002_625",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.07597535934292,0,"PD","","PROGRESSIVE DISEASE"
"307","PSIVISSIG0002",626,"PSIVISSIG0002_626",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.881587953456537,0,"PD","","DEATH"
"308","PSIVISSIG0002",627,"PSIVISSIG0002_627",44,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.53114305270363,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"309","PSIVISSIG0002",628,"PSIVISSIG0002_628",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.86447638603696,0,"PD","","PHYSICIAN DECISION"
"310","PSIVISSIG0002",630,"PSIVISSIG0002_630",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.709103353867214,0,"PD","","PROGRESSIVE DISEASE"
"311","PSIVISSIG0002",633,"PSIVISSIG0002_633",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.6208076659822,1,"Second next-line therapy initiated","Censored at the end date of the next-line therapy","PROGRESSIVE DISEASE"
"312","PSIVISSIG0002",634,"PSIVISSIG0002_634",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.72210814510609,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"313","PSIVISSIG0002",637,"PSIVISSIG0002_637",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.65913757700205,0,"Death","","PROGRESSIVE DISEASE"
"314","PSIVISSIG0002",638,"PSIVISSIG0002_638",43,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.01505817932923,0,"PD","","PROGRESSIVE DISEASE"
"315","PSIVISSIG0002",640,"PSIVISSIG0002_640",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.785763175906913,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"316","PSIVISSIG0002",644,"PSIVISSIG0002_644",76,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.6974674880219,1,"No next-line therapy initiated","Censored at the last contact date",""
"317","PSIVISSIG0002",645,"PSIVISSIG0002_645",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.35797399041752,0,"PD","","PROGRESSIVE DISEASE"
"318","PSIVISSIG0002",647,"PSIVISSIG0002_647",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.21560574948665,1,"Ongoing on first next-line therapy","Censored at the last contact date","PHYSICIAN DECISION"
"319","PSIVISSIG0002",649,"PSIVISSIG0002_649",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.29500342231348,0,"PD","","PROGRESSIVE DISEASE"
"320","PSIVISSIG0002",650,"PSIVISSIG0002_650",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.681724845995893,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"321","PSIVISSIG0002",653,"PSIVISSIG0002_653",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.58247775496235,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"322","PSIVISSIG0002",654,"PSIVISSIG0002_654",55,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.59958932238193,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"323","PSIVISSIG0002",655,"PSIVISSIG0002_655",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.24572210814511,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"324","PSIVISSIG0002",656,"PSIVISSIG0002_656",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.04243668720055,1,"No next-line therapy initiated","Censored at the last contact date",""
"325","PSIVISSIG0002",657,"PSIVISSIG0002_657",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.68788501026694,1,"No next-line therapy initiated","Censored at the last contact date",""
"326","PSIVISSIG0002",658,"PSIVISSIG0002_658",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.94866529774127,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"327","PSIVISSIG0002",660,"PSIVISSIG0002_660",74,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.67488021902806,1,"No next-line therapy initiated","Censored at the last contact date",""
"328","PSIVISSIG0002",661,"PSIVISSIG0002_661",65,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.323066392881588,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"329","PSIVISSIG0002",662,"PSIVISSIG0002_662",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.74401095140315,0,"PD","","PROGRESSIVE DISEASE"
"330","PSIVISSIG0002",663,"PSIVISSIG0002_663",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.86584531143053,1,"No next-line therapy initiated","Censored at the last contact date",""
"331","PSIVISSIG0002",664,"PSIVISSIG0002_664",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.5242984257358,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"332","PSIVISSIG0002",667,"PSIVISSIG0002_667",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.97399041752225,1,"No next-line therapy initiated","Censored at the last contact date",""
"333","PSIVISSIG0002",668,"PSIVISSIG0002_668",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.34702258726899,0,"PD","","PROGRESSIVE DISEASE"
"334","PSIVISSIG0002",669,"PSIVISSIG0002_669",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.03696098562628,0,"Death","","DEATH"
"335","PSIVISSIG0002",670,"PSIVISSIG0002_670",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.4154688569473,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"336","PSIVISSIG0002",671,"PSIVISSIG0002_671",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.320328542094456,0,"Death","","PROGRESSIVE DISEASE"
"337","PSIVISSIG0002",674,"PSIVISSIG0002_674",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.05065023956194,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"338","PSIVISSIG0002",676,"PSIVISSIG0002_676",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.6009582477755,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"339","PSIVISSIG0002",677,"PSIVISSIG0002_677",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.23203285420945,1,"Ongoing on first next-line therapy","Censored at the last contact date","PHYSICIAN DECISION"
"340","PSIVISSIG0002",678,"PSIVISSIG0002_678",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.84736481861739,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"341","PSIVISSIG0002",680,"PSIVISSIG0002_680",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.69952087611225,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"342","PSIVISSIG0002",685,"PSIVISSIG0002_685",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.681724845995893,0,"Death","","PHYSICIAN DECISION"
"343","PSIVISSIG0002",686,"PSIVISSIG0002_686",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.76591375770021,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"344","PSIVISSIG0002",689,"PSIVISSIG0002_689",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.65160848733744,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"345","PSIVISSIG0002",690,"PSIVISSIG0002_690",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.678986995208761,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"346","PSIVISSIG0002",695,"PSIVISSIG0002_695",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.69062286105407,1,"No next-line therapy initiated","Censored at the last contact date",""
"347","PSIVISSIG0002",697,"PSIVISSIG0002_697",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.21013004791239,0,"PD","","PROGRESSIVE DISEASE"
"348","PSIVISSIG0002",700,"PSIVISSIG0002_700",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.08966461327858,0,"PD","","PROGRESSIVE DISEASE"
"349","PSIVISSIG0002",702,"PSIVISSIG0002_702",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.17248459958932,1,"No next-line therapy initiated","Censored at the last contact date",""
"350","PSIVISSIG0002",704,"PSIVISSIG0002_704",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.86447638603696,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"351","PSIVISSIG0002",705,"PSIVISSIG0002_705",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.75154004106776,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"352","PSIVISSIG0002",706,"PSIVISSIG0002_706",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.87337440109514,0,"PD","","PROGRESSIVE DISEASE"
"353","PSIVISSIG0002",708,"PSIVISSIG0002_708",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.353182751540041,0,"Death","","PROGRESSIVE DISEASE"
"354","PSIVISSIG0002",709,"PSIVISSIG0002_709",69,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.87816563997262,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"355","PSIVISSIG0002",710,"PSIVISSIG0002_710",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.8993839835729,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"356","PSIVISSIG0002",712,"PSIVISSIG0002_712",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.98151950718686,0,"PD","","PROGRESSIVE DISEASE"
"357","PSIVISSIG0002",714,"PSIVISSIG0002_714",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.520191649555099,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"358","PSIVISSIG0002",715,"PSIVISSIG0002_715",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.47296372347707,0,"PD","","PROGRESSIVE DISEASE"
"359","PSIVISSIG0002",716,"PSIVISSIG0002_716",48,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.331279945242984,0,"Death","","PROTOCOL DEVIATION"
"360","PSIVISSIG0002",722,"PSIVISSIG0002_722",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.97399041752225,1,"No next-line therapy initiated","Censored at the last contact date",""
"361","PSIVISSIG0002",724,"PSIVISSIG0002_724",56,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.1088295687885,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"362","PSIVISSIG0002",725,"PSIVISSIG0002_725",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.648870636550308,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"363","PSIVISSIG0002",726,"PSIVISSIG0002_726",69,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.75564681724846,1,"No next-line therapy initiated","Censored at the last contact date",""
"364","PSIVISSIG0002",727,"PSIVISSIG0002_727",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.67008898015058,0,"Death","","PROGRESSIVE DISEASE"
"365","PSIVISSIG0002",728,"PSIVISSIG0002_728",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.5845311430527,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"366","PSIVISSIG0002",730,"PSIVISSIG0002_730",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.884325804243669,0,"PD","","PROGRESSIVE DISEASE"
"367","PSIVISSIG0002",731,"PSIVISSIG0002_731",55,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.591375770020534,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"368","PSIVISSIG0002",732,"PSIVISSIG0002_732",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.271047227926078,0,"Death","","DEATH"
"369","PSIVISSIG0002",736,"PSIVISSIG0002_736",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.03696098562628,0,"Death","","DEATH"
"370","PSIVISSIG0002",738,"PSIVISSIG0002_738",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.19096509240246,0,"PD","","PROGRESSIVE DISEASE"
"371","PSIVISSIG0002",739,"PSIVISSIG0002_739",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.84804928131417,1,"Ongoing on first next-line therapy","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"372","PSIVISSIG0002",740,"PSIVISSIG0002_740",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.59548254620123,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"373","PSIVISSIG0002",741,"PSIVISSIG0002_741",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.58932238193018,0,"Death","","PROGRESSIVE DISEASE"
"374","PSIVISSIG0002",742,"PSIVISSIG0002_742",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.323066392881588,1,"No next-line therapy initiated","Censored at the last contact date",""
"375","PSIVISSIG0002",743,"PSIVISSIG0002_743",43,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.503764544832307,0,"PD","","PROTOCOL DEVIATION"
"376","PSIVISSIG0002",745,"PSIVISSIG0002_745",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.97399041752225,0,"PD","","PROGRESSIVE DISEASE"
"377","PSIVISSIG0002",746,"PSIVISSIG0002_746",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.72484599589322,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"378","PSIVISSIG0002",748,"PSIVISSIG0002_748",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.00479123887748,0,"Death","","PROGRESSIVE DISEASE"
"379","PSIVISSIG0002",749,"PSIVISSIG0002_749",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.11430527036277,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"380","PSIVISSIG0002",751,"PSIVISSIG0002_751",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.213552361396304,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"381","PSIVISSIG0002",752,"PSIVISSIG0002_752",61,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.637234770705,0,"PD","","PROGRESSIVE DISEASE"
"382","PSIVISSIG0002",753,"PSIVISSIG0002_753",40,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.484599589322382,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"383","PSIVISSIG0002",756,"PSIVISSIG0002_756",73,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.51950718685832,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"384","PSIVISSIG0002",758,"PSIVISSIG0002_758",71,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.459958932238193,0,"Death","","PHYSICIAN DECISION"
"385","PSIVISSIG0002",759,"PSIVISSIG0002_759",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.320328542094456,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"386","PSIVISSIG0002",761,"PSIVISSIG0002_761",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.03285420944558,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"387","PSIVISSIG0002",762,"PSIVISSIG0002_762",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.927446954141,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"388","PSIVISSIG0002",763,"PSIVISSIG0002_763",56,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.164271047227926,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"389","PSIVISSIG0002",764,"PSIVISSIG0002_764",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.832306639288159,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"390","PSIVISSIG0002",766,"PSIVISSIG0002_766",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.91375770020534,0,"PD","","PROGRESSIVE DISEASE"
"391","PSIVISSIG0002",767,"PSIVISSIG0002_767",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.396988364134155,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"392","PSIVISSIG0002",768,"PSIVISSIG0002_768",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.941820670773443,0,"PD","","PROGRESSIVE DISEASE"
"393","PSIVISSIG0002",769,"PSIVISSIG0002_769",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.61875427789186,1,"No next-line therapy initiated","Censored at the last contact date",""
"394","PSIVISSIG0002",774,"PSIVISSIG0002_774",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.32169746748802,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"395","PSIVISSIG0002",775,"PSIVISSIG0002_775",69,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.56878850102669,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"396","PSIVISSIG0002",776,"PSIVISSIG0002_776",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.70225872689938,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"397","PSIVISSIG0002",777,"PSIVISSIG0002_777",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.08350444900753,1,"No next-line therapy initiated","Censored at the last contact date",""
"398","PSIVISSIG0002",780,"PSIVISSIG0002_780",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.657084188911704,0,"Death","","PHYSICIAN DECISION"
"399","PSIVISSIG0002",781,"PSIVISSIG0002_781",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.71868583162218,0,"PD","","PROGRESSIVE DISEASE"
"400","PSIVISSIG0002",782,"PSIVISSIG0002_782",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.813141683778234,0,"PD","","PROGRESSIVE DISEASE"
"401","PSIVISSIG0002",783,"PSIVISSIG0002_783",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.980150581793292,0,"Death","","PROGRESSIVE DISEASE"
"402","PSIVISSIG0002",784,"PSIVISSIG0002_784",66,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.854209445585216,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"403","PSIVISSIG0002",785,"PSIVISSIG0002_785",45,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.70362765229295,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"404","PSIVISSIG0002",788,"PSIVISSIG0002_788",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.77686516084873,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"405","PSIVISSIG0002",789,"PSIVISSIG0002_789",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.788501026694045,1,"No next-line therapy initiated","Censored at the last contact date",""
"406","PSIVISSIG0002",790,"PSIVISSIG0002_790",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.69952087611225,0,"PD","","PROGRESSIVE DISEASE"
"407","PSIVISSIG0002",791,"PSIVISSIG0002_791",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.60027378507871,1,"No next-line therapy initiated","Censored at the last contact date",""
"408","PSIVISSIG0002",792,"PSIVISSIG0002_792",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.57631759069131,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"409","PSIVISSIG0002",793,"PSIVISSIG0002_793",85,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.120465434633812,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"410","PSIVISSIG0002",797,"PSIVISSIG0002_797",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.94113620807666,0,"PD","","PROGRESSIVE DISEASE"
"411","PSIVISSIG0002",798,"PSIVISSIG0002_798",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.462696783025325,1,"No next-line therapy initiated","Censored at the last contact date",""
"412","PSIVISSIG0002",801,"PSIVISSIG0002_801",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.5927446954141,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"413","PSIVISSIG0002",802,"PSIVISSIG0002_802",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.818617385352498,0,"Death","","PROGRESSIVE DISEASE"
"414","PSIVISSIG0002",807,"PSIVISSIG0002_807",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.240930869267625,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"415","PSIVISSIG0002",810,"PSIVISSIG0002_810",62,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.695414099931554,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"416","PSIVISSIG0002",811,"PSIVISSIG0002_811",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.98083504449008,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"417","PSIVISSIG0002",815,"PSIVISSIG0002_815",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.229979466119097,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"418","PSIVISSIG0002",816,"PSIVISSIG0002_816",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.51882272416153,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"419","PSIVISSIG0002",817,"PSIVISSIG0002_817",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.665297741273101,0,"Death","","PROGRESSIVE DISEASE"
"420","PSIVISSIG0002",818,"PSIVISSIG0002_818",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.32717316906229,1,"No next-line therapy initiated","Censored at the last contact date",""
"421","PSIVISSIG0002",819,"PSIVISSIG0002_819",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.11430527036277,0,"PD","","PROGRESSIVE DISEASE"
"422","PSIVISSIG0002",821,"PSIVISSIG0002_821",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.2662559890486,1,"No next-line therapy initiated","Censored at the last contact date",""
"423","PSIVISSIG0002",823,"PSIVISSIG0002_823",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.40451745379877,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"424","PSIVISSIG0002",824,"PSIVISSIG0002_824",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.97946611909651,0,"PD","","PROGRESSIVE DISEASE"
"425","PSIVISSIG0002",825,"PSIVISSIG0002_825",46,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.695414099931554,0,"PD","","PROGRESSIVE DISEASE"
"426","PSIVISSIG0002",832,"PSIVISSIG0002_832",45,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.922655715263518,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"427","PSIVISSIG0002",834,"PSIVISSIG0002_834",75,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.88090349075975,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"428","PSIVISSIG0002",836,"PSIVISSIG0002_836",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.69130732375086,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"429","PSIVISSIG0002",837,"PSIVISSIG0002_837",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.07049965776865,1,"Ongoing on first next-line therapy","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"430","PSIVISSIG0002",838,"PSIVISSIG0002_838",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.92470910335387,0,"Death","","PROGRESSIVE DISEASE"
"431","PSIVISSIG0002",841,"PSIVISSIG0002_841",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.53319644079398,0,"PD","","PROGRESSIVE DISEASE"
"432","PSIVISSIG0002",843,"PSIVISSIG0002_843",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.23477070499658,0,"PD","","PROGRESSIVE DISEASE"
"433","PSIVISSIG0002",844,"PSIVISSIG0002_844",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.19849418206708,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"434","PSIVISSIG0002",848,"PSIVISSIG0002_848",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.43463381245722,0,"PD","","PROGRESSIVE DISEASE"
"435","PSIVISSIG0002",850,"PSIVISSIG0002_850",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.33812457221081,1,"No next-line therapy initiated","Censored at the last contact date",""
"436","PSIVISSIG0002",851,"PSIVISSIG0002_851",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.36824093086927,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"437","PSIVISSIG0002",852,"PSIVISSIG0002_852",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.24161533196441,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"438","PSIVISSIG0002",853,"PSIVISSIG0002_853",38,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.632443531827515,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"439","PSIVISSIG0002",856,"PSIVISSIG0002_856",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.76454483230664,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"440","PSIVISSIG0002",858,"PSIVISSIG0002_858",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.621492128678987,0,"Death","","DEATH"
"441","PSIVISSIG0002",861,"PSIVISSIG0002_861",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.09377138945927,0,"PD","","PROGRESSIVE DISEASE"
"442","PSIVISSIG0002",864,"PSIVISSIG0002_864",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.76796714579055,0,"PD","","PROGRESSIVE DISEASE"
"443","PSIVISSIG0002",865,"PSIVISSIG0002_865",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.74332648870637,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"444","PSIVISSIG0002",866,"PSIVISSIG0002_866",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.97741273100616,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"445","PSIVISSIG0002",867,"PSIVISSIG0002_867",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.62628336755647,0,"PD","","PROGRESSIVE DISEASE"
"446","PSIVISSIG0002",871,"PSIVISSIG0002_871",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.99110198494182,0,"Death","","PROGRESSIVE DISEASE"
"447","PSIVISSIG0002",873,"PSIVISSIG0002_873",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.26146475017112,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"448","PSIVISSIG0002",876,"PSIVISSIG0002_876",61,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.64271047227926,0,"PD","","PROGRESSIVE DISEASE"
"449","PSIVISSIG0002",877,"PSIVISSIG0002_877",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.55099247091034,0,"PD","","PROGRESSIVE DISEASE"
"450","PSIVISSIG0002",878,"PSIVISSIG0002_878",92,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.92128678986995,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"451","PSIVISSIG0002",883,"PSIVISSIG0002_883",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.950034223134839,0,"PD","","PROGRESSIVE DISEASE"
"452","PSIVISSIG0002",884,"PSIVISSIG0002_884",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.678986995208761,0,"Death","","PROGRESSIVE DISEASE"
"453","PSIVISSIG0002",885,"PSIVISSIG0002_885",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.3223819301848,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"454","PSIVISSIG0002",889,"PSIVISSIG0002_889",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.28678986995209,0,"PD","","PROGRESSIVE DISEASE"
"455","PSIVISSIG0002",893,"PSIVISSIG0002_893",82,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.43189596167009,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"456","PSIVISSIG0002",901,"PSIVISSIG0002_901",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.72484599589322,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"457","PSIVISSIG0002",905,"PSIVISSIG0002_905",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.18754277891855,1,"No next-line therapy initiated","Censored at the last contact date",""
"458","PSIVISSIG0002",909,"PSIVISSIG0002_909",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.56741957563313,0,"PD","","PROGRESSIVE DISEASE"
"459","PSIVISSIG0002",910,"PSIVISSIG0002_910",60,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.845995893223819,0,"PD","","PROGRESSIVE DISEASE"
"460","PSIVISSIG0002",912,"PSIVISSIG0002_912",73,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.50581793292266,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"461","PSIVISSIG0002",914,"PSIVISSIG0002_914",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.39082819986311,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"462","PSIVISSIG0002",915,"PSIVISSIG0002_915",46,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.736481861738535,0,"PD","","PROGRESSIVE DISEASE"
"463","PSIVISSIG0002",917,"PSIVISSIG0002_917",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.6974674880219,0,"PD","","PROGRESSIVE DISEASE"
"464","PSIVISSIG0002",919,"PSIVISSIG0002_919",47,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.514715947980835,1,"No next-line therapy initiated","Censored at the last contact date","PROTOCOL DEVIATION"
"465","PSIVISSIG0002",922,"PSIVISSIG0002_922",46,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.35592060232717,0,"PD","","PROGRESSIVE DISEASE"
"466","PSIVISSIG0002",923,"PSIVISSIG0002_923",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.92676249144422,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"467","PSIVISSIG0002",925,"PSIVISSIG0002_925",84,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.388774811772758,0,"Death","","DEATH"
"468","PSIVISSIG0002",927,"PSIVISSIG0002_927",50,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.410677618069815,0,"Death","","PROGRESSIVE DISEASE"
"469","PSIVISSIG0002",930,"PSIVISSIG0002_930",48,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.42984257357974,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"470","PSIVISSIG0002",931,"PSIVISSIG0002_931",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.64271047227926,0,"PD","","PROGRESSIVE DISEASE"
"471","PSIVISSIG0002",933,"PSIVISSIG0002_933",65,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.509240246406571,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"472","PSIVISSIG0002",935,"PSIVISSIG0002_935",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.97604380561259,1,"No next-line therapy initiated","Censored at the last contact date",""
"473","PSIVISSIG0002",936,"PSIVISSIG0002_936",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.26967830253251,1,"No next-line therapy initiated","Censored at the last contact date",""
"474","PSIVISSIG0002",939,"PSIVISSIG0002_939",77,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.2539356605065,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"475","PSIVISSIG0002",940,"PSIVISSIG0002_940",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.02053388090349,0,"PD","","PROGRESSIVE DISEASE"
"476","PSIVISSIG0002",941,"PSIVISSIG0002_941",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.97741273100616,1,"No next-line therapy initiated","Censored at the last contact date",""
"477","PSIVISSIG0002",943,"PSIVISSIG0002_943",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.08829568788501,1,"No next-line therapy initiated","Censored at the last contact date",""
"478","PSIVISSIG0002",945,"PSIVISSIG0002_945",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.362765229295,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"479","PSIVISSIG0002",946,"PSIVISSIG0002_946",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.68993839835729,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"480","PSIVISSIG0002",947,"PSIVISSIG0002_947",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.08966461327858,1,"Ongoing on first next-line therapy","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"481","PSIVISSIG0002",951,"PSIVISSIG0002_951",66,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.676249144421629,1,"No next-line therapy initiated","Censored at the last contact date",""
"482","PSIVISSIG0002",955,"PSIVISSIG0002_955",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.76591375770021,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"483","PSIVISSIG0002",961,"PSIVISSIG0002_961",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.32443531827515,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"484","PSIVISSIG0002",962,"PSIVISSIG0002_962",82,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.54140999315537,0,"PD","","ADVERSE EVENT"
"485","PSIVISSIG0002",964,"PSIVISSIG0002_964",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.78507871321013,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"486","PSIVISSIG0002",965,"PSIVISSIG0002_965",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.94113620807666,0,"PD","","PROGRESSIVE DISEASE"
"487","PSIVISSIG0002",967,"PSIVISSIG0002_967",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.720054757015743,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"488","PSIVISSIG0002",968,"PSIVISSIG0002_968",52,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.97604380561259,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"489","PSIVISSIG0002",970,"PSIVISSIG0002_970",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.79260780287474,0,"PD","","PROGRESSIVE DISEASE"
"490","PSIVISSIG0002",972,"PSIVISSIG0002_972",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.04791238877481,0,"PD","","PROGRESSIVE DISEASE"
"491","PSIVISSIG0002",974,"PSIVISSIG0002_974",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.22108145106092,1,"Ongoing on first next-line therapy","Censored at the last contact date","PHYSICIAN DECISION"
"492","PSIVISSIG0002",975,"PSIVISSIG0002_975",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.301163586584531,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"493","PSIVISSIG0002",976,"PSIVISSIG0002_976",89,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.44832306639288,0,"Death","","PROGRESSIVE DISEASE"
"494","PSIVISSIG0002",979,"PSIVISSIG0002_979",32,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.63791923340178,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"495","PSIVISSIG0002",980,"PSIVISSIG0002_980",54,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.94387405886379,0,"PD","","PROGRESSIVE DISEASE"
"496","PSIVISSIG0002",983,"PSIVISSIG0002_983",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.38193018480493,1,"No next-line therapy initiated","Censored at the last contact date",""
"497","PSIVISSIG0002",984,"PSIVISSIG0002_984",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.528405201916496,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"498","PSIVISSIG0002",985,"PSIVISSIG0002_985",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.59958932238193,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"499","PSIVISSIG0002",987,"PSIVISSIG0002_987",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.76112251882272,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"500","PSIVISSIG0002",988,"PSIVISSIG0002_988",61,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.637234770705,0,"PD","","PROGRESSIVE DISEASE"
"501","PSIVISSIG0002",989,"PSIVISSIG0002_989",69,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.832306639288159,0,"Death","","PROGRESSIVE DISEASE"
"502","PSIVISSIG0002",990,"PSIVISSIG0002_990",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.93223819301848,1,"No next-line therapy initiated","Censored at the last contact date",""
"503","PSIVISSIG0002",991,"PSIVISSIG0002_991",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.01505817932923,0,"PD","","PROGRESSIVE DISEASE"
"504","PSIVISSIG0002",992,"PSIVISSIG0002_992",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.28131416837782,0,"PD","","PROGRESSIVE DISEASE"
"505","PSIVISSIG0002",994,"PSIVISSIG0002_994",71,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.413415468856947,0,"Death","","PHYSICIAN DECISION"
"506","PSIVISSIG0002",995,"PSIVISSIG0002_995",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.2258726899384,0,"Death","","PROGRESSIVE DISEASE"
"507","PSIVISSIG0002",997,"PSIVISSIG0002_997",79,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.42505133470226,0,"Death","","DEATH"
"508","PSIVISSIG0002",998,"PSIVISSIG0002_998",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.31074606433949,1,"No next-line therapy initiated","Censored at the last contact date",""
"509","PSIVISSIG0002",999,"PSIVISSIG0002_999",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.01642710472279,1,"No next-line therapy initiated","Censored at the last contact date",""
"510","PSIVISSIG0002",1000,"PSIVISSIG0002_1000",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.11909650924025,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"511","PSIVISSIG0002",1001,"PSIVISSIG0002_1001",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.640657084188912,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"512","PSIVISSIG0002",1003,"PSIVISSIG0002_1003",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.29500342231348,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"513","PSIVISSIG0002",1006,"PSIVISSIG0002_1006",40,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.470910335386721,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"514","PSIVISSIG0002",1007,"PSIVISSIG0002_1007",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.5564681724846,1,"No next-line therapy initiated","Censored at the last contact date",""
"515","PSIVISSIG0002",1009,"PSIVISSIG0002_1009",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.28405201916496,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"516","PSIVISSIG0002",1010,"PSIVISSIG0002_1010",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.8062970568104,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"517","PSIVISSIG0002",1012,"PSIVISSIG0002_1012",89,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.47843942505133,0,"Death","","PROGRESSIVE DISEASE"
"518","PSIVISSIG0002",1013,"PSIVISSIG0002_1013",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.960985626283368,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"519","PSIVISSIG0002",1016,"PSIVISSIG0002_1016",74,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.66666666666667,1,"No next-line therapy initiated","Censored at the last contact date",""
"520","PSIVISSIG0002",1019,"PSIVISSIG0002_1019",43,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.48186173853525,0,"PD","","PROTOCOL DEVIATION"
"521","PSIVISSIG0002",1020,"PSIVISSIG0002_1020",46,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.31759069130732,0,"PD","","PROGRESSIVE DISEASE"
"522","PSIVISSIG0002",1021,"PSIVISSIG0002_1021",82,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.52772073921971,0,"PD","","ADVERSE EVENT"
"523","PSIVISSIG0002",1023,"PSIVISSIG0002_1023",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.684462696783025,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"524","PSIVISSIG0002",1027,"PSIVISSIG0002_1027",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.97878165639973,1,"No next-line therapy initiated","Censored at the last contact date",""
"525","PSIVISSIG0002",1028,"PSIVISSIG0002_1028",78,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.71937029431896,0,"Death","","PROGRESSIVE DISEASE"
"526","PSIVISSIG0002",1032,"PSIVISSIG0002_1032",72,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.97399041752225,0,"PD","","PROGRESSIVE DISEASE"
"527","PSIVISSIG0002",1033,"PSIVISSIG0002_1033",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.94866529774127,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"528","PSIVISSIG0002",1034,"PSIVISSIG0002_1034",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.1533196440794,1,"No next-line therapy initiated","Censored at the last contact date",""
"529","PSIVISSIG0002",1037,"PSIVISSIG0002_1037",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.48186173853525,1,"No next-line therapy initiated","Censored at the last contact date",""
"530","PSIVISSIG0002",1038,"PSIVISSIG0002_1038",41,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.186173853524983,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"531","PSIVISSIG0002",1040,"PSIVISSIG0002_1040",83,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.12525667351129,1,"No next-line therapy initiated","Censored at the last contact date",""
"532","PSIVISSIG0002",1042,"PSIVISSIG0002_1042",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.65639972621492,0,"Death","","PROGRESSIVE DISEASE"
"533","PSIVISSIG0002",1044,"PSIVISSIG0002_1044",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.4757015742642,0,"PD","","PROGRESSIVE DISEASE"
"534","PSIVISSIG0002",1045,"PSIVISSIG0002_1045",52,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.180698151950719,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"535","PSIVISSIG0002",1046,"PSIVISSIG0002_1046",55,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.90828199863107,0,"PD","","PROGRESSIVE DISEASE"
"536","PSIVISSIG0002",1049,"PSIVISSIG0002_1049",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.950034223134839,0,"PD","","PROGRESSIVE DISEASE"
"537","PSIVISSIG0002",1050,"PSIVISSIG0002_1050",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.08692676249144,0,"PD","","PROGRESSIVE DISEASE"
"538","PSIVISSIG0002",1055,"PSIVISSIG0002_1055",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.12525667351129,0,"PD","","PROGRESSIVE DISEASE"
"539","PSIVISSIG0002",1056,"PSIVISSIG0002_1056",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.25667351129363,0,"PD","","PROGRESSIVE DISEASE"
"540","PSIVISSIG0002",1057,"PSIVISSIG0002_1057",52,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.177960301163587,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"541","PSIVISSIG0002",1058,"PSIVISSIG0002_1058",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.16221765913758,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"542","PSIVISSIG0002",1059,"PSIVISSIG0002_1059",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.4435318275154,1,"No next-line therapy initiated","Censored at the last contact date",""
"543","PSIVISSIG0002",1060,"PSIVISSIG0002_1060",69,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.818617385352498,0,"Death","","PROGRESSIVE DISEASE"
"544","PSIVISSIG0002",1061,"PSIVISSIG0002_1061",62,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.670773442847365,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"545","PSIVISSIG0002",1062,"PSIVISSIG0002_1062",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.24161533196441,1,"No next-line therapy initiated","Censored at the last contact date",""
"546","PSIVISSIG0002",1065,"PSIVISSIG0002_1065",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.01779603011636,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"547","PSIVISSIG0002",1067,"PSIVISSIG0002_1067",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.78097193702943,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"548","PSIVISSIG0002",1068,"PSIVISSIG0002_1068",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.21834360027379,0,"Death","","PROGRESSIVE DISEASE"
"549","PSIVISSIG0002",1070,"PSIVISSIG0002_1070",73,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.93839835728953,0,"PD","","PROGRESSIVE DISEASE"
"550","PSIVISSIG0002",1073,"PSIVISSIG0002_1073",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.69472963723477,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"551","PSIVISSIG0002",1074,"PSIVISSIG0002_1074",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.00889801505818,1,"No next-line therapy initiated","Censored at the last contact date",""
"552","PSIVISSIG0002",1076,"PSIVISSIG0002_1076",45,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.654346338124572,0,"PD","","PROGRESSIVE DISEASE"
"553","PSIVISSIG0002",1081,"PSIVISSIG0002_1081",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.3709787816564,1,"No next-line therapy initiated","Censored at the last contact date",""
"554","PSIVISSIG0002",1082,"PSIVISSIG0002_1082",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.35455167693361,1,"No next-line therapy initiated","Censored at the last contact date",""
"555","PSIVISSIG0002",1083,"PSIVISSIG0002_1083",65,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.544832306639288,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"556","PSIVISSIG0002",1085,"PSIVISSIG0002_1085",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.829568788501027,0,"PD","","PROGRESSIVE DISEASE"
"557","PSIVISSIG0002",1088,"PSIVISSIG0002_1088",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.08281998631075,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"558","PSIVISSIG0002",1089,"PSIVISSIG0002_1089",75,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.17932922655715,0,"PD","","PROGRESSIVE DISEASE"
"559","PSIVISSIG0002",1093,"PSIVISSIG0002_1093",77,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.27857631759069,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"560","PSIVISSIG0002",1096,"PSIVISSIG0002_1096",66,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.08692676249144,0,"Death","","PROGRESSIVE DISEASE"
"561","PSIVISSIG0002",1099,"PSIVISSIG0002_1099",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.96509240246407,1,"No next-line therapy initiated","Censored at the last contact date",""
"562","PSIVISSIG0002",1101,"PSIVISSIG0002_1101",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.94934976043806,1,"No next-line therapy initiated","Censored at the last contact date",""
"563","PSIVISSIG0002",1103,"PSIVISSIG0002_1103",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.793976728268309,1,"No next-line therapy initiated","Censored at the last contact date",""
"564","PSIVISSIG0002",1104,"PSIVISSIG0002_1104",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.2943189596167,1,"No next-line therapy initiated","Censored at the last contact date",""
"565","PSIVISSIG0002",1105,"PSIVISSIG0002_1105",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.878850102669405,0,"PD","","DEATH"
"566","PSIVISSIG0002",1109,"PSIVISSIG0002_1109",53,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.59616700889802,0,"PD","","PROGRESSIVE DISEASE"
"567","PSIVISSIG0002",1111,"PSIVISSIG0002_1111",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.09514031485284,0,"PD","","PROGRESSIVE DISEASE"
"568","PSIVISSIG0002",1112,"PSIVISSIG0002_1112",42,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.698151950718686,0,"Death","","PROGRESSIVE DISEASE"
"569","PSIVISSIG0002",1115,"PSIVISSIG0002_1115",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.27583846680356,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"570","PSIVISSIG0002",1116,"PSIVISSIG0002_1116",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.933607118412047,0,"PD","","PROGRESSIVE DISEASE"
"571","PSIVISSIG0002",1117,"PSIVISSIG0002_1117",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.68104038329911,0,"Death","","PROGRESSIVE DISEASE"
"572","PSIVISSIG0002",1118,"PSIVISSIG0002_1118",84,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.43394934976044,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"573","PSIVISSIG0002",1119,"PSIVISSIG0002_1119",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.05338809034908,0,"Death","","PROGRESSIVE DISEASE"
"574","PSIVISSIG0002",1121,"PSIVISSIG0002_1121",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.10335386721424,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"575","PSIVISSIG0002",1123,"PSIVISSIG0002_1123",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.01232032854209,0,"Death","","DEATH"
"576","PSIVISSIG0002",1124,"PSIVISSIG0002_1124",74,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.73169062286105,1,"No next-line therapy initiated","Censored at the last contact date",""
"577","PSIVISSIG0002",1125,"PSIVISSIG0002_1125",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.8788501026694,1,"Ongoing on first next-line therapy","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"578","PSIVISSIG0002",1127,"PSIVISSIG0002_1127",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.48665297741273,0,"PD","","PROGRESSIVE DISEASE"
"579","PSIVISSIG0002",1129,"PSIVISSIG0002_1129",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",5.30321697467488,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"580","PSIVISSIG0002",1132,"PSIVISSIG0002_1132",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.87953456536619,1,"No next-line therapy initiated","Censored at the last contact date",""
"581","PSIVISSIG0002",1138,"PSIVISSIG0002_1138",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.698151950718686,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"582","PSIVISSIG0002",1140,"PSIVISSIG0002_1140",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.364134154688569,0,"Death","","PROGRESSIVE DISEASE"
"583","PSIVISSIG0002",1143,"PSIVISSIG0002_1143",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.97056810403833,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"584","PSIVISSIG0002",1148,"PSIVISSIG0002_1148",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.851471594798084,0,"PD","","PROGRESSIVE DISEASE"
"585","PSIVISSIG0002",1150,"PSIVISSIG0002_1150",50,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.8507871321013,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"586","PSIVISSIG0002",1153,"PSIVISSIG0002_1153",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.34907597535934,1,"No next-line therapy initiated","Censored at the last contact date",""
"587","PSIVISSIG0002",1154,"PSIVISSIG0002_1154",62,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.353182751540041,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"588","PSIVISSIG0002",1156,"PSIVISSIG0002_1156",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.03969883641342,0,"PD","","PROGRESSIVE DISEASE"
"589","PSIVISSIG0002",1157,"PSIVISSIG0002_1157",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.77138945927447,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"590","PSIVISSIG0002",1158,"PSIVISSIG0002_1158",52,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.99520876112252,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"591","PSIVISSIG0002",1159,"PSIVISSIG0002_1159",45,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.684462696783025,0,"PD","","PROGRESSIVE DISEASE"
"592","PSIVISSIG0002",1161,"PSIVISSIG0002_1161",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.28131416837782,0,"PD","","PROGRESSIVE DISEASE"
"593","PSIVISSIG0002",1162,"PSIVISSIG0002_1162",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.1129363449692,0,"PD","","PROGRESSIVE DISEASE"
"594","PSIVISSIG0002",1163,"PSIVISSIG0002_1163",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.276522929500342,0,"Death","","DEATH"
"595","PSIVISSIG0002",1165,"PSIVISSIG0002_1165",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.68377823408624,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"596","PSIVISSIG0002",1166,"PSIVISSIG0002_1166",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.17932922655715,0,"PD","","PROGRESSIVE DISEASE"
"597","PSIVISSIG0002",1167,"PSIVISSIG0002_1167",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.31143052703628,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"598","PSIVISSIG0002",1168,"PSIVISSIG0002_1168",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.1937029431896,0,"PD","","PROGRESSIVE DISEASE"
"599","PSIVISSIG0002",1174,"PSIVISSIG0002_1174",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.339493497604381,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"600","PSIVISSIG0002",1175,"PSIVISSIG0002_1175",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.90759753593429,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"601","PSIVISSIG0002",1176,"PSIVISSIG0002_1176",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.1895961670089,1,"No next-line therapy initiated","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"602","PSIVISSIG0002",1178,"PSIVISSIG0002_1178",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.21013004791239,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"603","PSIVISSIG0002",1179,"PSIVISSIG0002_1179",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.22792607802875,1,"No next-line therapy initiated","Censored at the last contact date",""
"604","PSIVISSIG0002",1180,"PSIVISSIG0002_1180",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.62628336755647,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"605","PSIVISSIG0002",1181,"PSIVISSIG0002_1181",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.04106776180698,1,"No next-line therapy initiated","Censored at the last contact date",""
"606","PSIVISSIG0002",1186,"PSIVISSIG0002_1186",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.05133470225873,0,"PD","","PHYSICIAN DECISION"
"607","PSIVISSIG0002",1188,"PSIVISSIG0002_1188",79,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.4031485284052,0,"Death","","DEATH"
"608","PSIVISSIG0002",1190,"PSIVISSIG0002_1190",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.802190280629706,0,"PD","","PROGRESSIVE DISEASE"
"609","PSIVISSIG0002",1191,"PSIVISSIG0002_1191",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.1492128678987,0,"PD","","PROGRESSIVE DISEASE"
"610","PSIVISSIG0002",1192,"PSIVISSIG0002_1192",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.15195071868583,1,"No next-line therapy initiated","Censored at the last contact date",""
"611","PSIVISSIG0002",1194,"PSIVISSIG0002_1194",82,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.4072553045859,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"612","PSIVISSIG0002",1196,"PSIVISSIG0002_1196",62,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.361396303901437,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"613","PSIVISSIG0002",1197,"PSIVISSIG0002_1197",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.1731690622861,0,"PD","","PROGRESSIVE DISEASE"
"614","PSIVISSIG0002",1199,"PSIVISSIG0002_1199",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.31895961670089,1,"No next-line therapy initiated","Censored at the last contact date",""
"615","PSIVISSIG0002",1201,"PSIVISSIG0002_1201",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.20054757015743,1,"No next-line therapy initiated","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"616","PSIVISSIG0002",1202,"PSIVISSIG0002_1202",55,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.93292265571526,0,"PD","","PROGRESSIVE DISEASE"
"617","PSIVISSIG0002",1205,"PSIVISSIG0002_1205",50,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.81245722108145,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"618","PSIVISSIG0002",1206,"PSIVISSIG0002_1206",52,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.659822039698836,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"619","PSIVISSIG0002",1208,"PSIVISSIG0002_1208",82,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.39082819986311,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"620","PSIVISSIG0002",1209,"PSIVISSIG0002_1209",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.72210814510609,0,"PD","","PROGRESSIVE DISEASE"
"621","PSIVISSIG0002",1213,"PSIVISSIG0002_1213",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.14236824093087,1,"No next-line therapy initiated","Censored at the last contact date",""
"622","PSIVISSIG0002",1215,"PSIVISSIG0002_1215",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.23203285420945,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"623","PSIVISSIG0002",1216,"PSIVISSIG0002_1216",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.17180013689254,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"624","PSIVISSIG0002",1222,"PSIVISSIG0002_1222",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.64818617385353,0,"PD","","PROGRESSIVE DISEASE"
"625","PSIVISSIG0002",1224,"PSIVISSIG0002_1224",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.47775496235455,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"626","PSIVISSIG0002",1226,"PSIVISSIG0002_1226",81,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.8145106091718,1,"No next-line therapy initiated","Censored at the last contact date",""
"627","PSIVISSIG0002",1227,"PSIVISSIG0002_1227",46,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.720054757015743,0,"PD","","PROGRESSIVE DISEASE"
"628","PSIVISSIG0002",1229,"PSIVISSIG0002_1229",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.21149897330595,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"629","PSIVISSIG0002",1230,"PSIVISSIG0002_1230",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.01848049281314,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"630","PSIVISSIG0002",1231,"PSIVISSIG0002_1231",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.79260780287474,0,"PD","","PROGRESSIVE DISEASE"
"631","PSIVISSIG0002",1232,"PSIVISSIG0002_1232",54,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.941820670773443,0,"Death","","DEATH"
"632","PSIVISSIG0002",1233,"PSIVISSIG0002_1233",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.87337440109514,0,"PD","","PROGRESSIVE DISEASE"
"633","PSIVISSIG0002",1234,"PSIVISSIG0002_1234",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.996577686516085,0,"Death","","PROGRESSIVE DISEASE"
"634","PSIVISSIG0002",1236,"PSIVISSIG0002_1236",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.04654346338125,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"635","PSIVISSIG0002",1237,"PSIVISSIG0002_1237",44,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.53661875427789,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"636","PSIVISSIG0002",1239,"PSIVISSIG0002_1239",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.61122518822724,1,"No next-line therapy initiated","Censored at the last contact date",""
"637","PSIVISSIG0002",1240,"PSIVISSIG0002_1240",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.28405201916496,0,"PD","","PROGRESSIVE DISEASE"
"638","PSIVISSIG0002",1244,"PSIVISSIG0002_1244",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.98973305954825,1,"No next-line therapy initiated","Censored at the last contact date",""
"639","PSIVISSIG0002",1247,"PSIVISSIG0002_1247",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.70294318959617,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"640","PSIVISSIG0002",1248,"PSIVISSIG0002_1248",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.25530458590007,1,"No next-line therapy initiated","Censored at the last contact date",""
"641","PSIVISSIG0002",1250,"PSIVISSIG0002_1250",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.98973305954825,1,"No next-line therapy initiated","Censored at the last contact date",""
"642","PSIVISSIG0002",1253,"PSIVISSIG0002_1253",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.67214236824093,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"643","PSIVISSIG0002",1254,"PSIVISSIG0002_1254",60,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.851471594798084,0,"PD","","PROGRESSIVE DISEASE"
"644","PSIVISSIG0002",1257,"PSIVISSIG0002_1257",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.41820670773443,0,"Death","","PROGRESSIVE DISEASE"
"645","PSIVISSIG0002",1265,"PSIVISSIG0002_1265",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.25667351129363,0,"PD","","PROGRESSIVE DISEASE"
"646","PSIVISSIG0002",1266,"PSIVISSIG0002_1266",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.31964407939767,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"647","PSIVISSIG0002",1267,"PSIVISSIG0002_1267",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.503764544832307,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"648","PSIVISSIG0002",1269,"PSIVISSIG0002_1269",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.11430527036277,0,"PD","","PROGRESSIVE DISEASE"
"649","PSIVISSIG0002",1271,"PSIVISSIG0002_1271",50,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.402464065708419,0,"Death","","PROGRESSIVE DISEASE"
"650","PSIVISSIG0002",1273,"PSIVISSIG0002_1273",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.80561259411362,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"651","PSIVISSIG0002",1274,"PSIVISSIG0002_1274",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.96098562628337,0,"Death","","PROGRESSIVE DISEASE"
"652","PSIVISSIG0002",1275,"PSIVISSIG0002_1275",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.89048596851472,1,"No next-line therapy initiated","Censored at the last contact date",""
"653","PSIVISSIG0002",1277,"PSIVISSIG0002_1277",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.99452429842574,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"654","PSIVISSIG0002",1278,"PSIVISSIG0002_1278",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.86447638603696,1,"No next-line therapy initiated","Censored at the last contact date",""
"655","PSIVISSIG0002",1280,"PSIVISSIG0002_1280",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.05338809034908,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"656","PSIVISSIG0002",1281,"PSIVISSIG0002_1281",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.32922655715264,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"657","PSIVISSIG0002",1283,"PSIVISSIG0002_1283",48,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.131416837782341,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"658","PSIVISSIG0002",1284,"PSIVISSIG0002_1284",43,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.490075290896646,0,"PD","","PROTOCOL DEVIATION"
"659","PSIVISSIG0002",1287,"PSIVISSIG0002_1287",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.26899383983573,1,"No next-line therapy initiated","Censored at the last contact date",""
"660","PSIVISSIG0002",1292,"PSIVISSIG0002_1292",56,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.84804928131417,0,"PD","","PROGRESSIVE DISEASE"
"661","PSIVISSIG0002",1293,"PSIVISSIG0002_1293",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.960985626283368,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"662","PSIVISSIG0002",1294,"PSIVISSIG0002_1294",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.796714579055442,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"663","PSIVISSIG0002",1297,"PSIVISSIG0002_1297",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.947296372347707,1,"No next-line therapy initiated","Censored at the last contact date",""
"664","PSIVISSIG0002",1298,"PSIVISSIG0002_1298",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.83983572895277,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"665","PSIVISSIG0002",1299,"PSIVISSIG0002_1299",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.1006160164271,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"666","PSIVISSIG0002",1300,"PSIVISSIG0002_1300",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.626967830253251,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"667","PSIVISSIG0002",1301,"PSIVISSIG0002_1301",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.09924709103354,0,"PD","","PROGRESSIVE DISEASE"
"668","PSIVISSIG0002",1302,"PSIVISSIG0002_1302",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.358658453114305,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"669","PSIVISSIG0002",1303,"PSIVISSIG0002_1303",45,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.92813141683778,1,"No next-line therapy initiated","Censored at the last contact date",""
"670","PSIVISSIG0002",1305,"PSIVISSIG0002_1305",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.810403832991102,0,"Death","","PROGRESSIVE DISEASE"
"671","PSIVISSIG0002",1306,"PSIVISSIG0002_1306",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.876112251882272,0,"Death","","PROGRESSIVE DISEASE"
"672","PSIVISSIG0002",1309,"PSIVISSIG0002_1309",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.65366187542779,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"673","PSIVISSIG0002",1311,"PSIVISSIG0002_1311",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.66735112936345,0,"PD","","PROGRESSIVE DISEASE"
"674","PSIVISSIG0002",1312,"PSIVISSIG0002_1312",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.68377823408624,0,"Death","","PROGRESSIVE DISEASE"
"675","PSIVISSIG0002",1314,"PSIVISSIG0002_1314",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.30047912388775,0,"Death","","PROGRESSIVE DISEASE"
"676","PSIVISSIG0002",1316,"PSIVISSIG0002_1316",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.09993155373032,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"677","PSIVISSIG0002",1318,"PSIVISSIG0002_1318",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.10198494182067,0,"PD","","PROGRESSIVE DISEASE"
"678","PSIVISSIG0002",1325,"PSIVISSIG0002_1325",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.50513347022587,0,"PD","","PROGRESSIVE DISEASE"
"679","PSIVISSIG0002",1326,"PSIVISSIG0002_1326",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.81177275838467,0,"PD","","PROGRESSIVE DISEASE"
"680","PSIVISSIG0002",1328,"PSIVISSIG0002_1328",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.791238877481177,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"681","PSIVISSIG0002",1329,"PSIVISSIG0002_1329",61,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.67830253251198,0,"PD","","PROGRESSIVE DISEASE"
"682","PSIVISSIG0002",1330,"PSIVISSIG0002_1330",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.072553045859,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"683","PSIVISSIG0002",1332,"PSIVISSIG0002_1332",52,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.98151950718686,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"684","PSIVISSIG0002",1334,"PSIVISSIG0002_1334",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.86447638603696,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"685","PSIVISSIG0002",1335,"PSIVISSIG0002_1335",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.56331279945243,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"686","PSIVISSIG0002",1336,"PSIVISSIG0002_1336",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.714579055441478,0,"PD","","PROGRESSIVE DISEASE"
"687","PSIVISSIG0002",1337,"PSIVISSIG0002_1337",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.16563997262149,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"688","PSIVISSIG0002",1338,"PSIVISSIG0002_1338",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.49418206707734,0,"PD","","PROGRESSIVE DISEASE"
"689","PSIVISSIG0002",1340,"PSIVISSIG0002_1340",32,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.65160848733744,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"690","PSIVISSIG0002",1341,"PSIVISSIG0002_1341",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.31416837782341,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"691","PSIVISSIG0002",1344,"PSIVISSIG0002_1344",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.5441478439425,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"692","PSIVISSIG0002",1345,"PSIVISSIG0002_1345",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.56331279945243,1,"No next-line therapy initiated","Censored at the last contact date",""
"693","PSIVISSIG0002",1348,"PSIVISSIG0002_1348",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.08692676249144,0,"PD","","PROGRESSIVE DISEASE"
"694","PSIVISSIG0002",1349,"PSIVISSIG0002_1349",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.68993839835729,0,"Death","","PROGRESSIVE DISEASE"
"695","PSIVISSIG0002",1352,"PSIVISSIG0002_1352",54,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.908966461327858,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"696","PSIVISSIG0002",1355,"PSIVISSIG0002_1355",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.824093086926763,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"697","PSIVISSIG0002",1356,"PSIVISSIG0002_1356",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.399726214921287,1,"No next-line therapy initiated","Censored at the last contact date",""
"698","PSIVISSIG0002",1357,"PSIVISSIG0002_1357",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.62765229295003,0,"Death","","PROGRESSIVE DISEASE"
"699","PSIVISSIG0002",1358,"PSIVISSIG0002_1358",84,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.43668720054757,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"700","PSIVISSIG0002",1359,"PSIVISSIG0002_1359",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.99315537303217,0,"PD","","PROGRESSIVE DISEASE"
"701","PSIVISSIG0002",1360,"PSIVISSIG0002_1360",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.856947296372348,0,"Death","","PROGRESSIVE DISEASE"
"702","PSIVISSIG0002",1361,"PSIVISSIG0002_1361",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.49691991786448,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"703","PSIVISSIG0002",1364,"PSIVISSIG0002_1364",66,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.1170431211499,0,"Death","","PROGRESSIVE DISEASE"
"704","PSIVISSIG0002",1367,"PSIVISSIG0002_1367",78,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.72758384668036,0,"Death","","PROGRESSIVE DISEASE"
"705","PSIVISSIG0002",1368,"PSIVISSIG0002_1368",45,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.903490759753593,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"706","PSIVISSIG0002",1369,"PSIVISSIG0002_1369",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.18685831622177,0,"Death","","SUBJECT/GUARDIAN DECISION"
"707","PSIVISSIG0002",1371,"PSIVISSIG0002_1371",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.681724845995893,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"708","PSIVISSIG0002",1373,"PSIVISSIG0002_1373",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.31006160164271,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"709","PSIVISSIG0002",1374,"PSIVISSIG0002_1374",69,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.86721423682409,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"710","PSIVISSIG0002",1375,"PSIVISSIG0002_1375",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.77138945927447,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"711","PSIVISSIG0002",1376,"PSIVISSIG0002_1376",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.17932922655715,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"712","PSIVISSIG0002",1380,"PSIVISSIG0002_1380",73,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.51676933607118,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"713","PSIVISSIG0002",1382,"PSIVISSIG0002_1382",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.8062970568104,0,"PD","","PROGRESSIVE DISEASE"
"714","PSIVISSIG0002",1383,"PSIVISSIG0002_1383",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.362765229295,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"715","PSIVISSIG0002",1384,"PSIVISSIG0002_1384",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.90212183436003,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"716","PSIVISSIG0002",1385,"PSIVISSIG0002_1385",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.9678302532512,1,"No next-line therapy initiated","Censored at the last contact date",""
"717","PSIVISSIG0002",1386,"PSIVISSIG0002_1386",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.826830937713895,0,"PD","","PROGRESSIVE DISEASE"
"718","PSIVISSIG0002",1387,"PSIVISSIG0002_1387",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.43737166324435,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"719","PSIVISSIG0002",1389,"PSIVISSIG0002_1389",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.643394934976044,0,"Death","","DEATH"
"720","PSIVISSIG0002",1390,"PSIVISSIG0002_1390",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.7296372347707,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"721","PSIVISSIG0002",1391,"PSIVISSIG0002_1391",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.98631074606434,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"722","PSIVISSIG0002",1392,"PSIVISSIG0002_1392",48,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.353182751540041,0,"Death","","PROTOCOL DEVIATION"
"723","PSIVISSIG0002",1394,"PSIVISSIG0002_1394",71,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.632443531827515,0,"PD","","PROGRESSIVE DISEASE"
"724","PSIVISSIG0002",1395,"PSIVISSIG0002_1395",46,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.36139630390144,0,"PD","","PROGRESSIVE DISEASE"
"725","PSIVISSIG0002",1396,"PSIVISSIG0002_1396",69,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.818617385352498,0,"Death","","PROGRESSIVE DISEASE"
"726","PSIVISSIG0002",1397,"PSIVISSIG0002_1397",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.00136892539357,1,"No next-line therapy initiated","Censored at the last contact date",""
"727","PSIVISSIG0002",1399,"PSIVISSIG0002_1399",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.388774811772758,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"728","PSIVISSIG0002",1402,"PSIVISSIG0002_1402",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.722792607802875,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"729","PSIVISSIG0002",1404,"PSIVISSIG0002_1404",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.04243668720055,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"730","PSIVISSIG0002",1405,"PSIVISSIG0002_1405",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.97604380561259,1,"No next-line therapy initiated","Censored at the last contact date",""
"731","PSIVISSIG0002",1406,"PSIVISSIG0002_1406",73,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.93292265571526,0,"PD","","PROGRESSIVE DISEASE"
"732","PSIVISSIG0002",1408,"PSIVISSIG0002_1408",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.5605749486653,1,"No next-line therapy initiated","Censored at the last contact date",""
"733","PSIVISSIG0002",1409,"PSIVISSIG0002_1409",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.1170431211499,0,"PD","","PROGRESSIVE DISEASE"
"734","PSIVISSIG0002",1410,"PSIVISSIG0002_1410",46,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.93702943189596,0,"PD","","PROGRESSIVE DISEASE"
"735","PSIVISSIG0002",1415,"PSIVISSIG0002_1415",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.468172484599589,0,"Death","","PROGRESSIVE DISEASE"
"736","PSIVISSIG0002",1416,"PSIVISSIG0002_1416",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.58658453114305,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"737","PSIVISSIG0002",1417,"PSIVISSIG0002_1417",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.71731690622861,0,"PD","","PROGRESSIVE DISEASE"
"738","PSIVISSIG0002",1419,"PSIVISSIG0002_1419",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.25667351129363,0,"PD","","PROGRESSIVE DISEASE"
"739","PSIVISSIG0002",1420,"PSIVISSIG0002_1420",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.65297741273101,1,"No next-line therapy initiated","Censored at the last contact date",""
"740","PSIVISSIG0002",1422,"PSIVISSIG0002_1422",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.5845311430527,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"741","PSIVISSIG0002",1423,"PSIVISSIG0002_1423",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.36824093086927,1,"No next-line therapy initiated","Censored at the last contact date",""
"742","PSIVISSIG0002",1424,"PSIVISSIG0002_1424",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.68377823408624,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"743","PSIVISSIG0002",1425,"PSIVISSIG0002_1425",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.8425735797399,0,"PD","","PROGRESSIVE DISEASE"
"744","PSIVISSIG0002",1426,"PSIVISSIG0002_1426",45,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.928131416837782,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"745","PSIVISSIG0002",1430,"PSIVISSIG0002_1430",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.947296372347707,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"746","PSIVISSIG0002",1431,"PSIVISSIG0002_1431",77,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.09514031485284,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"747","PSIVISSIG0002",1432,"PSIVISSIG0002_1432",83,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.10335386721424,1,"No next-line therapy initiated","Censored at the last contact date",""
"748","PSIVISSIG0002",1434,"PSIVISSIG0002_1434",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.71663244353183,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"749","PSIVISSIG0002",1436,"PSIVISSIG0002_1436",44,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.51745379876797,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"750","PSIVISSIG0002",1437,"PSIVISSIG0002_1437",74,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.70704996577687,1,"No next-line therapy initiated","Censored at the last contact date",""
"751","PSIVISSIG0002",1438,"PSIVISSIG0002_1438",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.28884325804244,1,"No next-line therapy initiated","Censored at the last contact date",""
"752","PSIVISSIG0002",1441,"PSIVISSIG0002_1441",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.9958932238193,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"753","PSIVISSIG0002",1444,"PSIVISSIG0002_1444",54,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.91170431211499,0,"Death","","DEATH"
"754","PSIVISSIG0002",1449,"PSIVISSIG0002_1449",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.20739219712526,0,"PD","","PROGRESSIVE DISEASE"
"755","PSIVISSIG0002",1452,"PSIVISSIG0002_1452",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.26009582477755,0,"Death","","DEATH"
"756","PSIVISSIG0002",1454,"PSIVISSIG0002_1454",61,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.63449691991786,0,"PD","","PROGRESSIVE DISEASE"
"757","PSIVISSIG0002",1457,"PSIVISSIG0002_1457",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.856947296372348,0,"PD","","PROGRESSIVE DISEASE"
"758","PSIVISSIG0002",1459,"PSIVISSIG0002_1459",55,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.94113620807666,0,"PD","","PROGRESSIVE DISEASE"
"759","PSIVISSIG0002",1461,"PSIVISSIG0002_1461",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.114989733059548,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"760","PSIVISSIG0002",1464,"PSIVISSIG0002_1464",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.14647501711157,1,"No next-line therapy initiated","Censored at the last contact date",""
"761","PSIVISSIG0002",1470,"PSIVISSIG0002_1470",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.290212183436003,0,"Death","","PROGRESSIVE DISEASE"
"762","PSIVISSIG0002",1472,"PSIVISSIG0002_1472",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.287474332648871,0,"Death","","PROGRESSIVE DISEASE"
"763","PSIVISSIG0002",1474,"PSIVISSIG0002_1474",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.93839835728953,0,"PD","","PROGRESSIVE DISEASE"
"764","PSIVISSIG0002",1479,"PSIVISSIG0002_1479",89,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.45379876796715,0,"Death","","PROGRESSIVE DISEASE"
"765","PSIVISSIG0002",1480,"PSIVISSIG0002_1480",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.804928131416838,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"766","PSIVISSIG0002",1481,"PSIVISSIG0002_1481",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.878850102669405,0,"PD","","PROGRESSIVE DISEASE"
"767","PSIVISSIG0002",1485,"PSIVISSIG0002_1485",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.70704996577687,1,"No next-line therapy initiated","Censored at the last contact date",""
"768","PSIVISSIG0002",1487,"PSIVISSIG0002_1487",44,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.5284052019165,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"769","PSIVISSIG0002",1489,"PSIVISSIG0002_1489",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.04859685147159,0,"PD","","PROGRESSIVE DISEASE"
"770","PSIVISSIG0002",1494,"PSIVISSIG0002_1494",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.50513347022587,1,"No next-line therapy initiated","Censored at the last contact date",""
"771","PSIVISSIG0002",1496,"PSIVISSIG0002_1496",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.22861054072553,0,"Death","","PROGRESSIVE DISEASE"
"772","PSIVISSIG0002",1498,"PSIVISSIG0002_1498",83,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.13894592744695,1,"No next-line therapy initiated","Censored at the last contact date",""
"773","PSIVISSIG0002",1505,"PSIVISSIG0002_1505",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.97330595482546,1,"No next-line therapy initiated","Censored at the last contact date",""
"774","PSIVISSIG0002",1507,"PSIVISSIG0002_1507",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.30321697467488,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"775","PSIVISSIG0002",1508,"PSIVISSIG0002_1508",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.42094455852156,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"776","PSIVISSIG0002",1509,"PSIVISSIG0002_1509",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.30869267624914,0,"PD","","PROGRESSIVE DISEASE"
"777","PSIVISSIG0002",1510,"PSIVISSIG0002_1510",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.298425735797399,0,"Death","","PROGRESSIVE DISEASE"
"778","PSIVISSIG0002",1513,"PSIVISSIG0002_1513",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.00958247775496,0,"PD","","PROGRESSIVE DISEASE"
"779","PSIVISSIG0002",1514,"PSIVISSIG0002_1514",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.514715947980835,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"780","PSIVISSIG0002",1516,"PSIVISSIG0002_1516",56,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.199863107460643,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"781","PSIVISSIG0002",1523,"PSIVISSIG0002_1523",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.24845995893224,1,"Ongoing on first next-line therapy","Censored at the last contact date","PHYSICIAN DECISION"
"782","PSIVISSIG0002",1525,"PSIVISSIG0002_1525",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.63997262149213,0,"PD","","PROGRESSIVE DISEASE"
"783","PSIVISSIG0002",1528,"PSIVISSIG0002_1528",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.18617385352498,1,"No next-line therapy initiated","Censored at the last contact date",""
"784","PSIVISSIG0002",1530,"PSIVISSIG0002_1530",57,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.57973990417522,0,"PD","","PROGRESSIVE DISEASE"
"785","PSIVISSIG0002",1532,"PSIVISSIG0002_1532",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.33812457221081,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"786","PSIVISSIG0002",1533,"PSIVISSIG0002_1533",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.22313483915127,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"787","PSIVISSIG0002",1534,"PSIVISSIG0002_1534",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.62354551676934,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"788","PSIVISSIG0002",1536,"PSIVISSIG0002_1536",65,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.514715947980835,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"789","PSIVISSIG0002",1537,"PSIVISSIG0002_1537",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.342231348391513,0,"Death","","PROGRESSIVE DISEASE"
"790","PSIVISSIG0002",1538,"PSIVISSIG0002_1538",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.16290212183436,1,"No next-line therapy initiated","Censored at the last contact date",""
"791","PSIVISSIG0002",1539,"PSIVISSIG0002_1539",45,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.9637234770705,1,"No next-line therapy initiated","Censored at the last contact date",""
"792","PSIVISSIG0002",1540,"PSIVISSIG0002_1540",69,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.85352498288843,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"793","PSIVISSIG0002",1541,"PSIVISSIG0002_1541",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.22245037645448,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"794","PSIVISSIG0002",1542,"PSIVISSIG0002_1542",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.72484599589322,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"795","PSIVISSIG0002",1543,"PSIVISSIG0002_1543",46,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.34770704996578,0,"PD","","PROGRESSIVE DISEASE"
"796","PSIVISSIG0002",1545,"PSIVISSIG0002_1545",88,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.958247775496235,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"797","PSIVISSIG0002",1548,"PSIVISSIG0002_1548",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.410677618069815,0,"Death","","PROGRESSIVE DISEASE"
"798","PSIVISSIG0002",1551,"PSIVISSIG0002_1551",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.13826146475017,0,"PD","","PROGRESSIVE DISEASE"
"799","PSIVISSIG0002",1552,"PSIVISSIG0002_1552",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.85352498288843,1,"No next-line therapy initiated","Censored at the last contact date",""
"800","PSIVISSIG0002",1554,"PSIVISSIG0002_1554",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.952772073921971,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"801","PSIVISSIG0002",1555,"PSIVISSIG0002_1555",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.20602327173169,0,"Death","","SUBJECT/GUARDIAN DECISION"
"802","PSIVISSIG0002",1556,"PSIVISSIG0002_1556",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.69130732375086,1,"No next-line therapy initiated","Censored at the last contact date",""
"803","PSIVISSIG0002",1557,"PSIVISSIG0002_1557",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.941820670773443,0,"PD","","PROGRESSIVE DISEASE"
"804","PSIVISSIG0002",1560,"PSIVISSIG0002_1560",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.06502395619439,0,"PD","","PROGRESSIVE DISEASE"
"805","PSIVISSIG0002",1562,"PSIVISSIG0002_1562",69,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.736481861738535,1,"No next-line therapy initiated","Censored at the last contact date",""
"806","PSIVISSIG0002",1565,"PSIVISSIG0002_1565",71,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.662559890485969,0,"PD","","PROGRESSIVE DISEASE"
"807","PSIVISSIG0002",1566,"PSIVISSIG0002_1566",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.83983572895277,1,"Ongoing on first next-line therapy","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"808","PSIVISSIG0002",1567,"PSIVISSIG0002_1567",76,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.71663244353183,1,"No next-line therapy initiated","Censored at the last contact date",""
"809","PSIVISSIG0002",1568,"PSIVISSIG0002_1568",48,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.358658453114305,0,"Death","","PROTOCOL DEVIATION"
"810","PSIVISSIG0002",1570,"PSIVISSIG0002_1570",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.65092402464066,0,"PD","","PROGRESSIVE DISEASE"
"811","PSIVISSIG0002",1571,"PSIVISSIG0002_1571",46,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.94524298425736,0,"PD","","PROGRESSIVE DISEASE"
"812","PSIVISSIG0002",1572,"PSIVISSIG0002_1572",43,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.188911704312115,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"813","PSIVISSIG0002",1574,"PSIVISSIG0002_1574",50,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.410677618069815,0,"Death","","PROGRESSIVE DISEASE"
"814","PSIVISSIG0002",1575,"PSIVISSIG0002_1575",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.85284052019165,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"815","PSIVISSIG0002",1576,"PSIVISSIG0002_1576",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.323066392881588,0,"Death","","PROGRESSIVE DISEASE"
"816","PSIVISSIG0002",1577,"PSIVISSIG0002_1577",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.27515400410678,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"817","PSIVISSIG0002",1579,"PSIVISSIG0002_1579",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.1047227926078,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"818","PSIVISSIG0002",1582,"PSIVISSIG0002_1582",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.31211498973306,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"819","PSIVISSIG0002",1589,"PSIVISSIG0002_1589",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.843258042436687,0,"PD","","PROGRESSIVE DISEASE"
"820","PSIVISSIG0002",1592,"PSIVISSIG0002_1592",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.15263518138261,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"821","PSIVISSIG0002",1593,"PSIVISSIG0002_1593",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.24298425735797,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"822","PSIVISSIG0002",1594,"PSIVISSIG0002_1594",57,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.56605065023956,0,"PD","","PROGRESSIVE DISEASE"
"823","PSIVISSIG0002",1598,"PSIVISSIG0002_1598",45,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.692676249144422,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"824","PSIVISSIG0002",1599,"PSIVISSIG0002_1599",77,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.08145106091718,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"825","PSIVISSIG0002",1601,"PSIVISSIG0002_1601",41,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.172484599589322,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"826","PSIVISSIG0002",1603,"PSIVISSIG0002_1603",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.53388090349076,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"827","PSIVISSIG0002",1604,"PSIVISSIG0002_1604",48,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.446269678302533,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"828","PSIVISSIG0002",1605,"PSIVISSIG0002_1605",77,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.29500342231348,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"829","PSIVISSIG0002",1608,"PSIVISSIG0002_1608",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.67556468172485,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"830","PSIVISSIG0002",1612,"PSIVISSIG0002_1612",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.73305954825462,0,"Death","","PROGRESSIVE DISEASE"
"831","PSIVISSIG0002",1616,"PSIVISSIG0002_1616",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.1088295687885,0,"PD","","PROGRESSIVE DISEASE"
"832","PSIVISSIG0002",1617,"PSIVISSIG0002_1617",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.358658453114305,1,"No next-line therapy initiated","Censored at the last contact date",""
"833","PSIVISSIG0002",1618,"PSIVISSIG0002_1618",65,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.364134154688569,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"834","PSIVISSIG0002",1619,"PSIVISSIG0002_1619",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.57973990417522,1,"No next-line therapy initiated","Censored at the last contact date",""
"835","PSIVISSIG0002",1620,"PSIVISSIG0002_1620",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.30047912388775,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"836","PSIVISSIG0002",1625,"PSIVISSIG0002_1625",52,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.03696098562628,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"837","PSIVISSIG0002",1626,"PSIVISSIG0002_1626",71,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.65160848733744,0,"PD","","PROGRESSIVE DISEASE"
"838","PSIVISSIG0002",1627,"PSIVISSIG0002_1627",81,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.659822039698836,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"839","PSIVISSIG0002",1628,"PSIVISSIG0002_1628",75,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.19028062970568,0,"PD","","PROGRESSIVE DISEASE"
"840","PSIVISSIG0002",1629,"PSIVISSIG0002_1629",43,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.490075290896646,0,"PD","","PROTOCOL DEVIATION"
"841","PSIVISSIG0002",1633,"PSIVISSIG0002_1633",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.34907597535934,1,"No next-line therapy initiated","Censored at the last contact date",""
"842","PSIVISSIG0002",1635,"PSIVISSIG0002_1635",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.75154004106776,0,"PD","","PROGRESSIVE DISEASE"
"843","PSIVISSIG0002",1636,"PSIVISSIG0002_1636",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.9958932238193,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"844","PSIVISSIG0002",1638,"PSIVISSIG0002_1638",74,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.68788501026694,1,"No next-line therapy initiated","Censored at the last contact date",""
"845","PSIVISSIG0002",1640,"PSIVISSIG0002_1640",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.73305954825462,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"846","PSIVISSIG0002",1641,"PSIVISSIG0002_1641",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.01779603011636,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"847","PSIVISSIG0002",1642,"PSIVISSIG0002_1642",72,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.00136892539357,0,"PD","","PROGRESSIVE DISEASE"
"848","PSIVISSIG0002",1644,"PSIVISSIG0002_1644",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.21286789869952,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"849","PSIVISSIG0002",1646,"PSIVISSIG0002_1646",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.42915811088296,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"850","PSIVISSIG0002",1648,"PSIVISSIG0002_1648",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.79808350444901,1,"No next-line therapy initiated","Censored at the last contact date",""
"851","PSIVISSIG0002",1650,"PSIVISSIG0002_1650",71,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.654346338124572,0,"PD","","PROGRESSIVE DISEASE"
"852","PSIVISSIG0002",1651,"PSIVISSIG0002_1651",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.9356605065024,0,"Death","","PROGRESSIVE DISEASE"
"853","PSIVISSIG0002",1653,"PSIVISSIG0002_1653",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.629705681040383,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"854","PSIVISSIG0002",1656,"PSIVISSIG0002_1656",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.37371663244353,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"855","PSIVISSIG0002",1658,"PSIVISSIG0002_1658",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.14442162902122,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"856","PSIVISSIG0002",1659,"PSIVISSIG0002_1659",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.56878850102669,0,"PD","","PROGRESSIVE DISEASE"
"857","PSIVISSIG0002",1660,"PSIVISSIG0002_1660",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.988364134154689,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"858","PSIVISSIG0002",1661,"PSIVISSIG0002_1661",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.96235455167693,0,"PD","","PROGRESSIVE DISEASE"
"859","PSIVISSIG0002",1662,"PSIVISSIG0002_1662",81,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.79260780287474,1,"No next-line therapy initiated","Censored at the last contact date",""
"860","PSIVISSIG0002",1663,"PSIVISSIG0002_1663",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.65639972621492,0,"PD","","PROGRESSIVE DISEASE"
"861","PSIVISSIG0002",1664,"PSIVISSIG0002_1664",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.76180698151951,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"862","PSIVISSIG0002",1665,"PSIVISSIG0002_1665",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.97878165639973,1,"No next-line therapy initiated","Censored at the last contact date",""
"863","PSIVISSIG0002",1666,"PSIVISSIG0002_1666",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.53798767967146,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"864","PSIVISSIG0002",1667,"PSIVISSIG0002_1667",48,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.353182751540041,0,"Death","","PROTOCOL DEVIATION"
"865","PSIVISSIG0002",1670,"PSIVISSIG0002_1670",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.77138945927447,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"866","PSIVISSIG0002",1675,"PSIVISSIG0002_1675",83,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.1006160164271,1,"No next-line therapy initiated","Censored at the last contact date",""
"867","PSIVISSIG0002",1679,"PSIVISSIG0002_1679",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.93839835728953,0,"Death","","PROGRESSIVE DISEASE"
"868","PSIVISSIG0002",1682,"PSIVISSIG0002_1682",51,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.97330595482546,1,"No next-line therapy initiated","Censored at the last contact date",""
"869","PSIVISSIG0002",1683,"PSIVISSIG0002_1683",84,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.358658453114305,0,"Death","","DEATH"
"870","PSIVISSIG0002",1684,"PSIVISSIG0002_1684",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.991101984941821,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"871","PSIVISSIG0002",1688,"PSIVISSIG0002_1688",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.89185489390828,1,"No next-line therapy initiated","Censored at the last contact date",""
"872","PSIVISSIG0002",1692,"PSIVISSIG0002_1692",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.90075290896646,1,"Ongoing on first next-line therapy","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"873","PSIVISSIG0002",1694,"PSIVISSIG0002_1694",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.89733059548255,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"874","PSIVISSIG0002",1696,"PSIVISSIG0002_1696",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.24024640657084,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"875","PSIVISSIG0002",1697,"PSIVISSIG0002_1697",53,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.61806981519507,0,"PD","","PROGRESSIVE DISEASE"
"876","PSIVISSIG0002",1698,"PSIVISSIG0002_1698",54,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.939082819986311,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"877","PSIVISSIG0002",1702,"PSIVISSIG0002_1702",81,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.616016427104723,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"878","PSIVISSIG0002",1703,"PSIVISSIG0002_1703",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.63175906913073,0,"PD","","PROGRESSIVE DISEASE"
"879","PSIVISSIG0002",1704,"PSIVISSIG0002_1704",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.75770020533881,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"880","PSIVISSIG0002",1706,"PSIVISSIG0002_1706",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.34633812457221,0,"PD","","PROGRESSIVE DISEASE"
"881","PSIVISSIG0002",1708,"PSIVISSIG0002_1708",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.87337440109514,0,"PD","","PROGRESSIVE DISEASE"
"882","PSIVISSIG0002",1715,"PSIVISSIG0002_1715",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.30800821355236,1,"No next-line therapy initiated","Censored at the last contact date",""
"883","PSIVISSIG0002",1716,"PSIVISSIG0002_1716",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.788501026694045,1,"No next-line therapy initiated","Censored at the last contact date",""
"884","PSIVISSIG0002",1717,"PSIVISSIG0002_1717",53,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.6208076659822,0,"PD","","PROGRESSIVE DISEASE"
"885","PSIVISSIG0002",1720,"PSIVISSIG0002_1720",54,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.95208761122519,0,"PD","","PROGRESSIVE DISEASE"
"886","PSIVISSIG0002",1722,"PSIVISSIG0002_1722",75,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.88911704312115,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"887","PSIVISSIG0002",1723,"PSIVISSIG0002_1723",78,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.73579739904175,0,"Death","","PROGRESSIVE DISEASE"
"888","PSIVISSIG0002",1724,"PSIVISSIG0002_1724",74,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.70431211498973,1,"No next-line therapy initiated","Censored at the last contact date",""
"889","PSIVISSIG0002",1726,"PSIVISSIG0002_1726",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.427104722792608,1,"No next-line therapy initiated","Censored at the last contact date",""
"890","PSIVISSIG0002",1727,"PSIVISSIG0002_1727",81,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.77344284736482,1,"No next-line therapy initiated","Censored at the last contact date",""
"891","PSIVISSIG0002",1728,"PSIVISSIG0002_1728",69,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.58521560574949,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"892","PSIVISSIG0002",1730,"PSIVISSIG0002_1730",32,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.632443531827515,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"893","PSIVISSIG0002",1733,"PSIVISSIG0002_1733",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.20944558521561,1,"No next-line therapy initiated","Censored at the last contact date",""
"894","PSIVISSIG0002",1734,"PSIVISSIG0002_1734",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.438056125941136,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"895","PSIVISSIG0002",1735,"PSIVISSIG0002_1735",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.34633812457221,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"896","PSIVISSIG0002",1737,"PSIVISSIG0002_1737",56,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.08692676249144,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"897","PSIVISSIG0002",1742,"PSIVISSIG0002_1742",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.19780971937029,0,"Death","","SUBJECT/GUARDIAN DECISION"
"898","PSIVISSIG0002",1743,"PSIVISSIG0002_1743",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.19780971937029,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"899","PSIVISSIG0002",1744,"PSIVISSIG0002_1744",55,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.91649555099247,0,"PD","","PROGRESSIVE DISEASE"
"900","PSIVISSIG0002",1745,"PSIVISSIG0002_1745",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.72073921971253,1,"No next-line therapy initiated","Censored at the last contact date",""
"901","PSIVISSIG0002",1747,"PSIVISSIG0002_1747",54,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.908966461327858,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"902","PSIVISSIG0002",1748,"PSIVISSIG0002_1748",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.12731006160164,0,"PD","","PROGRESSIVE DISEASE"
"903","PSIVISSIG0002",1751,"PSIVISSIG0002_1751",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.673511293634497,0,"Death","","PROGRESSIVE DISEASE"
"904","PSIVISSIG0002",1752,"PSIVISSIG0002_1752",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.75701574264203,0,"PD","","PROGRESSIVE DISEASE"
"905","PSIVISSIG0002",1753,"PSIVISSIG0002_1753",82,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.49760438056126,0,"PD","","ADVERSE EVENT"
"906","PSIVISSIG0002",1754,"PSIVISSIG0002_1754",77,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.25119780971937,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"907","PSIVISSIG0002",1756,"PSIVISSIG0002_1756",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.69952087611225,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"908","PSIVISSIG0002",1757,"PSIVISSIG0002_1757",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.71868583162218,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"909","PSIVISSIG0002",1758,"PSIVISSIG0002_1758",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.82067077344285,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"910","PSIVISSIG0002",1759,"PSIVISSIG0002_1759",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.939082819986311,1,"No next-line therapy initiated","Censored at the last contact date",""
"911","PSIVISSIG0002",1761,"PSIVISSIG0002_1761",66,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.829568788501027,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"912","PSIVISSIG0002",1763,"PSIVISSIG0002_1763",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.72689938398357,0,"PD","","PROGRESSIVE DISEASE"
"913","PSIVISSIG0002",1766,"PSIVISSIG0002_1766",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.388774811772758,0,"Death","","PROGRESSIVE DISEASE"
"914","PSIVISSIG0002",1767,"PSIVISSIG0002_1767",55,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.610540725530459,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"915","PSIVISSIG0002",1769,"PSIVISSIG0002_1769",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.84804928131417,1,"No next-line therapy initiated","Censored at the last contact date",""
"916","PSIVISSIG0002",1770,"PSIVISSIG0002_1770",57,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.57700205338809,0,"PD","","PROGRESSIVE DISEASE"
"917","PSIVISSIG0002",1771,"PSIVISSIG0002_1771",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.61806981519507,1,"Second next-line therapy initiated","Censored at the end date of the next-line therapy","PROGRESSIVE DISEASE"
"918","PSIVISSIG0002",1772,"PSIVISSIG0002_1772",55,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.490075290896646,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"919","PSIVISSIG0002",1776,"PSIVISSIG0002_1776",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.413415468856947,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"920","PSIVISSIG0002",1779,"PSIVISSIG0002_1779",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.36002737850787,1,"No next-line therapy initiated","Censored at the last contact date",""
"921","PSIVISSIG0002",1780,"PSIVISSIG0002_1780",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.57973990417522,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"922","PSIVISSIG0002",1783,"PSIVISSIG0002_1783",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.67008898015058,0,"PD","","PROGRESSIVE DISEASE"
"923","PSIVISSIG0002",1784,"PSIVISSIG0002_1784",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.4757015742642,0,"PD","","PROGRESSIVE DISEASE"
"924","PSIVISSIG0002",1785,"PSIVISSIG0002_1785",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.75154004106776,0,"PD","","PROGRESSIVE DISEASE"
"925","PSIVISSIG0002",1788,"PSIVISSIG0002_1788",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.30869267624914,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"926","PSIVISSIG0002",1789,"PSIVISSIG0002_1789",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.810403832991102,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"927","PSIVISSIG0002",1790,"PSIVISSIG0002_1790",38,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.632443531827515,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"928","PSIVISSIG0002",1792,"PSIVISSIG0002_1792",81,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.78439425051335,1,"No next-line therapy initiated","Censored at the last contact date",""
"929","PSIVISSIG0002",1793,"PSIVISSIG0002_1793",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.96235455167693,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"930","PSIVISSIG0002",1795,"PSIVISSIG0002_1795",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.361396303901437,0,"Death","","PROGRESSIVE DISEASE"
"931","PSIVISSIG0002",1796,"PSIVISSIG0002_1796",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.783025325119781,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"932","PSIVISSIG0002",1798,"PSIVISSIG0002_1798",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.72210814510609,0,"Death","","PROGRESSIVE DISEASE"
"933","PSIVISSIG0002",1799,"PSIVISSIG0002_1799",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.788501026694045,1,"No next-line therapy initiated","Censored at the last contact date",""
"934","PSIVISSIG0002",1806,"PSIVISSIG0002_1806",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.77618069815195,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"935","PSIVISSIG0002",1807,"PSIVISSIG0002_1807",66,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.08418891170431,0,"Death","","PROGRESSIVE DISEASE"
"936","PSIVISSIG0002",1809,"PSIVISSIG0002_1809",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.24709103353867,1,"No next-line therapy initiated","Censored at the last contact date",""
"937","PSIVISSIG0002",1814,"PSIVISSIG0002_1814",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.353182751540041,0,"Death","","PROGRESSIVE DISEASE"
"938","PSIVISSIG0002",1815,"PSIVISSIG0002_1815",45,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.58247775496235,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"939","PSIVISSIG0002",1816,"PSIVISSIG0002_1816",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.82067077344285,0,"PD","","PROGRESSIVE DISEASE"
"940","PSIVISSIG0002",1818,"PSIVISSIG0002_1818",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.95414099931554,1,"No next-line therapy initiated","Censored at the last contact date",""
"941","PSIVISSIG0002",1819,"PSIVISSIG0002_1819",81,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.654346338124572,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"942","PSIVISSIG0002",1821,"PSIVISSIG0002_1821",69,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.59069130732375,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"943","PSIVISSIG0002",1822,"PSIVISSIG0002_1822",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.89185489390828,1,"No next-line therapy initiated","Censored at the last contact date",""
"944","PSIVISSIG0002",1823,"PSIVISSIG0002_1823",85,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.101300479123888,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"945","PSIVISSIG0002",1826,"PSIVISSIG0002_1826",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.616016427104723,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"946","PSIVISSIG0002",1828,"PSIVISSIG0002_1828",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.9192334017796,1,"No next-line therapy initiated","Censored at the last contact date",""
"947","PSIVISSIG0002",1829,"PSIVISSIG0002_1829",47,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.525667351129363,1,"No next-line therapy initiated","Censored at the last contact date","PROTOCOL DEVIATION"
"948","PSIVISSIG0002",1831,"PSIVISSIG0002_1831",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.94592744695414,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"949","PSIVISSIG0002",1832,"PSIVISSIG0002_1832",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.82067077344285,1,"Ongoing on first next-line therapy","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"950","PSIVISSIG0002",1833,"PSIVISSIG0002_1833",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.780287474332649,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"951","PSIVISSIG0002",1839,"PSIVISSIG0002_1839",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.99794661190965,0,"PD","","PROGRESSIVE DISEASE"
"952","PSIVISSIG0002",1841,"PSIVISSIG0002_1841",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.00273785078713,1,"No next-line therapy initiated","Censored at the last contact date",""
"953","PSIVISSIG0002",1842,"PSIVISSIG0002_1842",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.59890485968515,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"954","PSIVISSIG0002",1843,"PSIVISSIG0002_1843",78,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.8425735797399,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"955","PSIVISSIG0002",1848,"PSIVISSIG0002_1848",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.00136892539357,0,"PD","","PROGRESSIVE DISEASE"
"956","PSIVISSIG0002",1860,"PSIVISSIG0002_1860",73,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.48665297741273,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"957","PSIVISSIG0002",1861,"PSIVISSIG0002_1861",40,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.511978097193703,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"958","PSIVISSIG0002",1862,"PSIVISSIG0002_1862",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",5.29774127310062,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"959","PSIVISSIG0002",1865,"PSIVISSIG0002_1865",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.77070499657769,0,"PD","","PROGRESSIVE DISEASE"
"960","PSIVISSIG0002",1866,"PSIVISSIG0002_1866",66,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.845995893223819,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"961","PSIVISSIG0002",1868,"PSIVISSIG0002_1868",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.643394934976044,0,"Death","","DEATH"
"962","PSIVISSIG0002",1869,"PSIVISSIG0002_1869",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.355920602327173,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"963","PSIVISSIG0002",1870,"PSIVISSIG0002_1870",62,"Negative",2,"Hormone receptor negative","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.709103353867214,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"964","PSIVISSIG0002",1872,"PSIVISSIG0002_1872",84,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.42573579739904,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"965","PSIVISSIG0002",1875,"PSIVISSIG0002_1875",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.90006844626968,0,"PD","","PROGRESSIVE DISEASE"
"966","PSIVISSIG0002",1878,"PSIVISSIG0002_1878",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.47775496235455,1,"No next-line therapy initiated","Censored at the last contact date",""
"967","PSIVISSIG0002",1881,"PSIVISSIG0002_1881",79,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.41409993155373,0,"Death","","DEATH"
"968","PSIVISSIG0002",1886,"PSIVISSIG0002_1886",63,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.810403832991102,1,"No next-line therapy initiated","Censored at the last contact date",""
"969","PSIVISSIG0002",1887,"PSIVISSIG0002_1887",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.36824093086927,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"970","PSIVISSIG0002",1889,"PSIVISSIG0002_1889",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.08145106091718,0,"PD","","PHYSICIAN DECISION"
"971","PSIVISSIG0002",1892,"PSIVISSIG0002_1892",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.48117727583847,0,"PD","","PROGRESSIVE DISEASE"
"972","PSIVISSIG0002",1893,"PSIVISSIG0002_1893",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.56262833675565,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"973","PSIVISSIG0002",1896,"PSIVISSIG0002_1896",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.08145106091718,0,"PD","","PROGRESSIVE DISEASE"
"974","PSIVISSIG0002",1897,"PSIVISSIG0002_1897",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.56331279945243,0,"PD","","PROGRESSIVE DISEASE"
"975","PSIVISSIG0002",1898,"PSIVISSIG0002_1898",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.16221765913758,0,"PD","","PROGRESSIVE DISEASE"
"976","PSIVISSIG0002",1899,"PSIVISSIG0002_1899",84,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.42573579739904,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"977","PSIVISSIG0002",1901,"PSIVISSIG0002_1901",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.9596167008898,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"978","PSIVISSIG0002",1907,"PSIVISSIG0002_1907",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.18206707734428,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"979","PSIVISSIG0002",1910,"PSIVISSIG0002_1910",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.56194387405886,1,"No next-line therapy initiated","Censored at the last contact date",""
"980","PSIVISSIG0002",1914,"PSIVISSIG0002_1914",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.98699520876112,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"981","PSIVISSIG0002",1915,"PSIVISSIG0002_1915",40,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.479123887748118,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"982","PSIVISSIG0002",1916,"PSIVISSIG0002_1916",62,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.974674880219028,0,"PD","","PROGRESSIVE DISEASE"
"983","PSIVISSIG0002",1918,"PSIVISSIG0002_1918",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.78439425051335,1,"No next-line therapy initiated","Censored at the last contact date",""
"984","PSIVISSIG0002",1919,"PSIVISSIG0002_1919",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.20739219712526,0,"Death","","PROGRESSIVE DISEASE"
"985","PSIVISSIG0002",1920,"PSIVISSIG0002_1920",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.71594798083504,0,"PD","","PROGRESSIVE DISEASE"
"986","PSIVISSIG0002",1921,"PSIVISSIG0002_1921",56,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.188911704312115,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"987","PSIVISSIG0002",1923,"PSIVISSIG0002_1923",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.07597535934292,0,"PD","","PROGRESSIVE DISEASE"
"988","PSIVISSIG0002",1926,"PSIVISSIG0002_1926",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.24161533196441,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"989","PSIVISSIG0002",1928,"PSIVISSIG0002_1928",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.47775496235455,0,"PD","","PROGRESSIVE DISEASE"
"990","PSIVISSIG0002",1929,"PSIVISSIG0002_1929",79,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.4031485284052,0,"Death","","DEATH"
"991","PSIVISSIG0002",1934,"PSIVISSIG0002_1934",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.43189596167009,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"992","PSIVISSIG0002",1935,"PSIVISSIG0002_1935",84,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.380561259411362,0,"Death","","DEATH"
"993","PSIVISSIG0002",1936,"PSIVISSIG0002_1936",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.04517453798768,0,"PD","","PROGRESSIVE DISEASE"
"994","PSIVISSIG0002",1940,"PSIVISSIG0002_1940",48,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.109514031485284,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"995","PSIVISSIG0002",1941,"PSIVISSIG0002_1941",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.96509240246407,1,"No next-line therapy initiated","Censored at the last contact date",""
"996","PSIVISSIG0002",1942,"PSIVISSIG0002_1942",85,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.0903490759753593,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"997","PSIVISSIG0002",1943,"PSIVISSIG0002_1943",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.97741273100616,0,"PD","","PROGRESSIVE DISEASE"
"998","PSIVISSIG0002",1947,"PSIVISSIG0002_1947",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.49418206707734,1,"No next-line therapy initiated","Censored at the last contact date",""
"999","PSIVISSIG0002",1950,"PSIVISSIG0002_1950",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.81724845995893,1,"Lost to follow-up","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"1000","PSIVISSIG0002",1952,"PSIVISSIG0002_1952",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.791238877481177,1,"No next-line therapy initiated","Censored at the last contact date",""
"1001","PSIVISSIG0002",1954,"PSIVISSIG0002_1954",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.49555099247091,0,"Death","","PROGRESSIVE DISEASE"
"1002","PSIVISSIG0002",1958,"PSIVISSIG0002_1958",78,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.74127310061602,0,"Death","","PROGRESSIVE DISEASE"
"1003","PSIVISSIG0002",1962,"PSIVISSIG0002_1962",67,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.698151950718686,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"1004","PSIVISSIG0002",1963,"PSIVISSIG0002_1963",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.47775496235455,1,"No next-line therapy initiated","Censored at the last contact date",""
"1005","PSIVISSIG0002",1965,"PSIVISSIG0002_1965",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.65639972621492,0,"Death","","PROGRESSIVE DISEASE"
"1006","PSIVISSIG0002",1966,"PSIVISSIG0002_1966",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.16016427104723,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1007","PSIVISSIG0002",1968,"PSIVISSIG0002_1968",76,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.67830253251198,0,"Death","","PROGRESSIVE DISEASE"
"1008","PSIVISSIG0002",1971,"PSIVISSIG0002_1971",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.77618069815195,0,"PD","","PROGRESSIVE DISEASE"
"1009","PSIVISSIG0002",1973,"PSIVISSIG0002_1973",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.92470910335387,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1010","PSIVISSIG0002",1978,"PSIVISSIG0002_1978",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.66392881587953,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1011","PSIVISSIG0002",1979,"PSIVISSIG0002_1979",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.835044490075291,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1012","PSIVISSIG0002",1982,"PSIVISSIG0002_1982",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.63997262149213,0,"Death","","PROGRESSIVE DISEASE"
"1013","PSIVISSIG0002",1983,"PSIVISSIG0002_1983",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.810403832991102,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1014","PSIVISSIG0002",1984,"PSIVISSIG0002_1984",38,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.657084188911704,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"1015","PSIVISSIG0002",1986,"PSIVISSIG0002_1986",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.52361396303901,0,"PD","","PROGRESSIVE DISEASE"
"1016","PSIVISSIG0002",1989,"PSIVISSIG0002_1989",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.32785763175907,0,"Death","","PROGRESSIVE DISEASE"
"1017","PSIVISSIG0002",1994,"PSIVISSIG0002_1994",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.49965776865161,0,"PD","","PROGRESSIVE DISEASE"
"1018","PSIVISSIG0002",1997,"PSIVISSIG0002_1997",66,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.12731006160164,0,"PD","","PROGRESSIVE DISEASE"
"1019","PSIVISSIG0002",1998,"PSIVISSIG0002_1998",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.8145106091718,0,"PD","","PROGRESSIVE DISEASE"
"1020","PSIVISSIG0002",1999,"PSIVISSIG0002_1999",55,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.531143052703628,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1021","PSIVISSIG0002",2000,"PSIVISSIG0002_2000",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.63175906913073,0,"PD","","PROGRESSIVE DISEASE"
"1022","PSIVISSIG0002",2001,"PSIVISSIG0002_2001",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.75975359342916,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1023","PSIVISSIG0002",2004,"PSIVISSIG0002_2004",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.98015058179329,0,"Death","","PROGRESSIVE DISEASE"
"1024","PSIVISSIG0002",2006,"PSIVISSIG0002_2006",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.668035592060233,0,"Death","","PROGRESSIVE DISEASE"
"1025","PSIVISSIG0002",2013,"PSIVISSIG0002_2013",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.00479123887748,0,"Death","","PROGRESSIVE DISEASE"
"1026","PSIVISSIG0002",2015,"PSIVISSIG0002_2015",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.89733059548255,1,"No next-line therapy initiated","Censored at the last contact date",""
"1027","PSIVISSIG0002",2017,"PSIVISSIG0002_2017",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.668035592060233,0,"Death","","PHYSICIAN DECISION"
"1028","PSIVISSIG0002",2018,"PSIVISSIG0002_2018",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.21149897330595,0,"Death","","SUBJECT/GUARDIAN DECISION"
"1029","PSIVISSIG0002",2020,"PSIVISSIG0002_2020",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.11225188227242,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1030","PSIVISSIG0002",2021,"PSIVISSIG0002_2021",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",4.75838466803559,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1031","PSIVISSIG0002",2023,"PSIVISSIG0002_2023",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.54688569472964,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1032","PSIVISSIG0002",2024,"PSIVISSIG0002_2024",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.68309377138946,1,"No next-line therapy initiated","Censored at the last contact date",""
"1033","PSIVISSIG0002",2026,"PSIVISSIG0002_2026",63,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.42094455852156,0,"Death","","PROGRESSIVE DISEASE"
"1034","PSIVISSIG0002",2027,"PSIVISSIG0002_2027",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.407939767282683,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1035","PSIVISSIG0002",2030,"PSIVISSIG0002_2030",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.21013004791239,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1036","PSIVISSIG0002",2034,"PSIVISSIG0002_2034",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.700889801505818,0,"Death","","PROGRESSIVE DISEASE"
"1037","PSIVISSIG0002",2038,"PSIVISSIG0002_2038",65,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.98151950718686,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1038","PSIVISSIG0002",2042,"PSIVISSIG0002_2042",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.42642026009582,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1039","PSIVISSIG0002",2043,"PSIVISSIG0002_2043",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.38740588637919,0,"Death","","PROGRESSIVE DISEASE"
"1040","PSIVISSIG0002",2045,"PSIVISSIG0002_2045",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.60027378507871,1,"No next-line therapy initiated","Censored at the last contact date",""
"1041","PSIVISSIG0002",2047,"PSIVISSIG0002_2047",43,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.167008898015058,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"1042","PSIVISSIG0002",2049,"PSIVISSIG0002_2049",46,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.720054757015743,0,"PD","","PROGRESSIVE DISEASE"
"1043","PSIVISSIG0002",2050,"PSIVISSIG0002_2050",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.358658453114305,0,"Death","","PROGRESSIVE DISEASE"
"1044","PSIVISSIG0002",2051,"PSIVISSIG0002_2051",57,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",4.61054072553046,1,"No next-line therapy initiated","Censored at the last contact date",""
"1045","PSIVISSIG0002",2059,"PSIVISSIG0002_2059",44,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.03490759753593,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1046","PSIVISSIG0002",2062,"PSIVISSIG0002_2062",70,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.82340862422998,0,"PD","","PROGRESSIVE DISEASE"
"1047","PSIVISSIG0002",2063,"PSIVISSIG0002_2063",64,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.70841889117043,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1048","PSIVISSIG0002",2064,"PSIVISSIG0002_2064",60,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.1895961670089,0,"PD","","PROGRESSIVE DISEASE"
"1049","PSIVISSIG0002",2067,"PSIVISSIG0002_2067",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.08898015058179,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1050","PSIVISSIG0002",2068,"PSIVISSIG0002_2068",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.375085557837098,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1051","PSIVISSIG0002",2073,"PSIVISSIG0002_2073",59,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.05133470225873,0,"PD","","PHYSICIAN DECISION"
"1052","PSIVISSIG0002",2074,"PSIVISSIG0002_2074",79,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.75496235455168,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1053","PSIVISSIG0002",2075,"PSIVISSIG0002_2075",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.04859685147159,1,"Ongoing on first next-line therapy","Censored at the last contact date","SUBJECT/GUARDIAN DECISION"
"1054","PSIVISSIG0002",2076,"PSIVISSIG0002_2076",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.26967830253251,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1055","PSIVISSIG0002",2077,"PSIVISSIG0002_2077",60,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.22655715263518,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1056","PSIVISSIG0002",2080,"PSIVISSIG0002_2080",72,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",3.70431211498973,1,"No next-line therapy initiated","Censored at the last contact date",""
"1057","PSIVISSIG0002",2083,"PSIVISSIG0002_2083",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.62354551676934,0,"PD","","PROGRESSIVE DISEASE"
"1058","PSIVISSIG0002",2084,"PSIVISSIG0002_2084",60,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.867898699520876,0,"PD","","PROGRESSIVE DISEASE"
"1059","PSIVISSIG0002",2086,"PSIVISSIG0002_2086",71,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.421629021218344,0,"Death","","PHYSICIAN DECISION"
"1060","PSIVISSIG0002",2088,"PSIVISSIG0002_2088",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.17453798767967,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1061","PSIVISSIG0002",2090,"PSIVISSIG0002_2090",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.87268993839836,0,"PD","","PHYSICIAN DECISION"
"1062","PSIVISSIG0002",2093,"PSIVISSIG0002_2093",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.668035592060233,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1063","PSIVISSIG0002",2098,"PSIVISSIG0002_2098",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.386036960985626,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1064","PSIVISSIG0002",2099,"PSIVISSIG0002_2099",51,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.80766598220397,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1065","PSIVISSIG0002",2100,"PSIVISSIG0002_2100",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.70020533880904,0,"PD","","PROGRESSIVE DISEASE"
"1066","PSIVISSIG0002",2104,"PSIVISSIG0002_2104",57,"Positive",1,"Hormone receptor positive","PRIOR USE",1,"Prior Radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.5605749486653,0,"PD","","PROGRESSIVE DISEASE"
"1067","PSIVISSIG0002",2111,"PSIVISSIG0002_2111",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.63997262149213,0,"PD","","PROGRESSIVE DISEASE"
"1068","PSIVISSIG0002",2115,"PSIVISSIG0002_2115",76,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.74127310061602,1,"No next-line therapy initiated","Censored at the last contact date",""
"1069","PSIVISSIG0002",2116,"PSIVISSIG0002_2116",48,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.451745379876797,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1070","PSIVISSIG0002",2118,"PSIVISSIG0002_2118",73,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.20054757015743,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1071","PSIVISSIG0002",2124,"PSIVISSIG0002_2124",58,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.89185489390828,1,"No next-line therapy initiated","Censored at the last contact date",""
"1072","PSIVISSIG0002",2127,"PSIVISSIG0002_2127",59,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.76796714579055,0,"PD","","PROGRESSIVE DISEASE"
"1073","PSIVISSIG0002",2128,"PSIVISSIG0002_2128",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.32443531827515,0,"PD","","PROGRESSIVE DISEASE"
"1074","PSIVISSIG0002",2129,"PSIVISSIG0002_2129",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.18822724161533,0,"PD","","PROGRESSIVE DISEASE"
"1075","PSIVISSIG0002",2130,"PSIVISSIG0002_2130",58,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.48870636550308,1,"No next-line therapy initiated","Censored at the last contact date",""
"1076","PSIVISSIG0002",2134,"PSIVISSIG0002_2134",68,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.31622176591376,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1077","PSIVISSIG0002",2137,"PSIVISSIG0002_2137",45,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.56331279945243,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1078","PSIVISSIG0002",2138,"PSIVISSIG0002_2138",56,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.0643394934976,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1079","PSIVISSIG0002",2139,"PSIVISSIG0002_2139",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.31279945242984,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1080","PSIVISSIG0002",2141,"PSIVISSIG0002_2141",57,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.5605749486653,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1081","PSIVISSIG0002",2142,"PSIVISSIG0002_2142",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.97262149212868,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1082","PSIVISSIG0002",2146,"PSIVISSIG0002_2146",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.70020533880904,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1083","PSIVISSIG0002",2148,"PSIVISSIG0002_2148",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.982888432580424,0,"PD","","PROGRESSIVE DISEASE"
"1084","PSIVISSIG0002",2150,"PSIVISSIG0002_2150",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.670773442847365,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1085","PSIVISSIG0002",2155,"PSIVISSIG0002_2155",71,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.94045174537988,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1086","PSIVISSIG0002",2158,"PSIVISSIG0002_2158",61,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.10335386721424,0,"PD","","PROGRESSIVE DISEASE"
"1087","PSIVISSIG0002",2159,"PSIVISSIG0002_2159",80,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.20944558521561,0,"Death","","PROGRESSIVE DISEASE"
"1088","PSIVISSIG0002",2161,"PSIVISSIG0002_2161",52,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.197125256673511,1,"Lost to follow-up","Censored at the last contact date","PROTOCOL DEVIATION"
"1089","PSIVISSIG0002",2162,"PSIVISSIG0002_2162",69,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.774811772758385,0,"PD","","PROGRESSIVE DISEASE"
"1090","PSIVISSIG0002",2165,"PSIVISSIG0002_2165",67,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",3.5564681724846,0,"PD","","PROGRESSIVE DISEASE"
"1091","PSIVISSIG0002",2167,"PSIVISSIG0002_2167",45,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.54140999315537,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1092","PSIVISSIG0002",2170,"PSIVISSIG0002_2170",72,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.92197125256674,1,"No next-line therapy initiated","Censored at the last contact date",""
"1093","PSIVISSIG0002",2171,"PSIVISSIG0002_2171",77,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.39561943874059,1,"Lost to follow-up","Censored at the last contact date","PROGRESSIVE DISEASE"
"1094","PSIVISSIG0002",2175,"PSIVISSIG0002_2175",55,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.01779603011636,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1095","PSIVISSIG0002",2176,"PSIVISSIG0002_2176",62,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",2.76796714579055,1,"No next-line therapy initiated","Censored at the last contact date",""
"1096","PSIVISSIG0002",2177,"PSIVISSIG0002_2177",75,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.87337440109514,0,"Death","","PROGRESSIVE DISEASE"
"1097","PSIVISSIG0002",2180,"PSIVISSIG0002_2180",69,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.824093086926763,0,"Death","","PROGRESSIVE DISEASE"
"1098","PSIVISSIG0002",2181,"PSIVISSIG0002_2181",74,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.85968514715948,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1099","PSIVISSIG0002",2184,"PSIVISSIG0002_2184",71,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.56605065023956,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1100","PSIVISSIG0002",2188,"PSIVISSIG0002_2188",50,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",1.76591375770021,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1101","PSIVISSIG0002",2190,"PSIVISSIG0002_2190",70,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.0903490759753593,1,"No next-line therapy initiated","Censored at the last contact date","PROGRESSIVE DISEASE"
"1102","PSIVISSIG0002",2192,"PSIVISSIG0002_2192",88,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",0.952772073921971,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1103","PSIVISSIG0002",2194,"PSIVISSIG0002_2194",64,"Positive",1,"Hormone receptor positive","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.99315537303217,1,"No next-line therapy initiated","Censored at the last contact date",""
"1104","PSIVISSIG0002",2197,"PSIVISSIG0002_2197",61,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",1.76317590691307,1,"Ongoing on first next-line therapy","Censored at the last contact date","PROGRESSIVE DISEASE"
"1105","PSIVISSIG0002",2198,"PSIVISSIG0002_2198",65,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","tablemab x 52 weeks",1,"Progression-free survival (years)","PFS",2.34633812457221,0,"Death","","PROGRESSIVE DISEASE"
"1106","PSIVISSIG0002",2199,"PSIVISSIG0002_2199",50,"Negative",2,"Hormone receptor negative","NO PRIOR USE",2,"No prior radiotherapy","vismab x 52 weeks",2,"Progression-free survival (years)","PFS",0.4435318275154,0,"Death","","PROGRESSIVE DISEASE"
